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Abstract 
Introduction 
Delayed ischaemic neurological deficit (DIND) following aneurysmal 
subarachnoid haemorrhage (aSAH) is a significant cause of morbidity and 
mortality.  There is some evidence to suggest that its pathogenesis is related 
to inflammation and that clearing the subarachnoid space of potential 
pathogens via a lumbar drain may reduce the prevalence and severity of 
DIND.  
Aims 
The aims of the current study are two-fold:  
1.  To ascertain whether lumbar drainage of cerebrospinal fluid (CSF) 
following aSAH can reduce the prevalence and severity of DIND.  
2.  To investigate levels of inflammatory mediators in plasma and CSF and to 
look for an association with aSAH, DIND and outcome. 
Material and methods 
1.  Prospective randomised controlled trial with randomisation into two arms: 
arm 1 control, no additional intervention; Arm 2 study, insertion of a lumbar 
drain in order to clear the visible blood load. 
2.  Prospective cohort study of patients with aSAH.  Plasma and CSF samples 
were obtained on days 3, 5, 7 and 9 following haemorrhage and analysed for 
11 mediators. 
 
Results 
1.  Prevalence of DIND 35% (confidence interval (CI) 26.2-45.2%) in the 
control versus 21% (CI 13.6-30.0%) in the study group (p=0.021).  A 
significant improvement in early clinical outcome in favour of lumbar drainage 
was noted (Modified Rankin Score 0-2 37.5% in the control versus 55.2% in 
the study group, p=0.009).  There was no difference in outcome at six 
months.  
2.  Raised plasma and CSF levels of most mediators when compared with 
non-aSAH controls.  Significantly higher levels of vascular endothelial growth 
factor within the CSF of patients with DIND on day 5 post ictus when 
compared to patients without DIND.  Generally higher mediator levels were 
noted within the CSF when compared to plasma. 
 
Conclusion 
This provides some support for the routine use of lumbar drains following 
aSAH in good grade patients to reduce the prevalence of DIND and improve 
early clinical outcome.  Both a central nervous system and systemic 
inflammatory response is initiated following aSAH.  The former may be 
associated with DIND.  Causality cannot be determined from this study.   
  
Introduction 
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Introduction 
 
The incidence of aneurysmal subarachnoid haemorrhage (aSAH) has been 
estimated at 6-8 per 100,000 annually, with a peak incidence in the fifth 
decade1. Delayed ischaemic neurological deficit (DIND) (also referred to as 
clinical/symptomatic vasospasm or delayed cerebral ischaemia) is a serious 
and poorly understood complication of aSAH, occurring in 20-40% of patients.  
This is characteristically defined as neurological deficit observed at least three 
days after aSAH, and features radiologically confirmed narrowing of the large 
cerebral blood vessels (radiological vasospasm).  However, it has increasingly 
been suggested that a direct causative association between the two may be 
overly simplistic, despite their following a similar time course2.  The variability 
in the reported incidence of DIND is partly due to the use of unstandardised 
diagnostic criteria. DIND does not necessarily imply the presence of 
angiographic vasospasm, although numerous studies have this (or a 
surrogate measure, such as flow velocities with transcranial doppler) as a 
prerequisite for diagnosis3. The observation that thick subarachnoid clot 
completely filling any cistern or fissure is an independent predictor of DIND 
suggests that causative compound(s) may be blood component(s), 
breakdown products, or be regulated/induced as a result of the presence of 
blood in or around the subarachnoid space4. 
 
The aim of this introduction is to: (i) summarise the main historical events 
resulting in the current understanding of DIND, (ii) discuss the evidence 
underlying established therapies for DIND, and (iii) broadly review the 
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translational and clinical research involved in elucidating the pathophysiology 
of DIND.  This will subsequently lead to the aims of the current study. 
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Historical overview 
 
Although ancient Egyptian writings indicated awareness of aneurysms, a 
causal association with subarachnoid haemorrhage was only first proposed in 
the late 1600s5.  Almost a century later, Morgagni reported incidental posterior 
cerebral artery dilatations, suggesting that intracranial aneurysms may be a 
source of haemorrhage6. In parallel, Francesco Biumi presented the first 
documented report of an unruptured intracranial aneurysm7, which was 
followed by the first verified account of aneurysmal rupture five decades 
later8. The earliest nineteenth century description of DIND came from William 
Gull, who described a young woman suffering a stroke and her subsequent 
neurological deterioration on the fifth day of her illness-she was shown to 
have a ruptured middle cerebral artery aneurysm at autopsy9. 
 
The first description of cerebral vasospasm was made in the 1920s, when 
rabbit cortical arteries were noted to contract following direct mechanical 
stimulus, but not in response to cervical sympathetic chain stimulation10.  
Current understanding of cerebrovascular abnormalities emerged following 
the work of Egas Moniz in developing clinical angiograms in the late 1920s11, 
an imaging approach which underpinned Norman Dott’s attempt at direct 
aneurysmal surgical repair and Walter Dandy’s subsequent successful 
surgical clip repair12.  Robertson’s large series of ruptured intracranial 
aneurysms highlighted the presence of cerebral infarction despite patent 
blood vessels13.  In the same period, Zucker described the presence of 
putative circulatory vasoconstrictive agents originating from lysed 
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erythrocytes14, a notion supported by Jackson’s observations that a 
meningeal reaction followed injection of blood products into the cisterna 
magna of dogs15, with red blood cells eliciting the greatest reaction.   
 
Cerebral vasospasm following aSAH was first described in Reid and 
Johnson’s angiographic studies16, although it was not until the following year 
that the images were published by Ecker and Riemenschneider17.  This 
landmark study reported six patients who had suffered angiographically visible 
vasospasm defined as a change in vessel calibre between two identically 
performed angiograms at different time intervals.  Angiographic vasospasm 
was noted to be self-limiting and greatest near the site of the aneurysm.  
Subsequent studies demonstrated a poorer operative prognosis, larger 
proportion of ischaemic lesions and worse outcome in patients with 
angiographic vasospasm18, which was related to reduced total or regional 
cerebral blood flow (CBF)19.  Techniques were developed to reduce the 
incidence of vasospasm during aneurysm surgery, including the timing of 
operations.  Allcock and Drake advocated delayed surgical treatment because 
of a higher incidence of vasospasm in patients treated within ten days of 
ictus20.  However, no consensus was reached regarding timing of surgery until 
1976, following the publication of a large case series which indicated that 
mortality was decreased and the risk of vasospasm reduced in patients 
undergoing surgery within 48 hours21.  In addition, an elegant study by Weir 
and colleagues based on serial angiograms in almost 300 patients 
demonstrated the onset, peak and subsidence of vasospasm at days 3, 6-8 
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and 12, respectively22.  Mortality was confirmed to relate to the presence and 
severity of vasospasm. 
 
Although the association between the size of the blood clot and the incidence 
of angiographic vasospasm is historically attributed to Fisher, it was Katada 
shortly followed by Takemae who were the first to report this association23,24.  
In 1980, the Fisher classification of aSAH was published25, which was based 
on a series of 47 patients with aSAH. It was noted that severe angiographic 
vasospasm was almost invariably present in patients with subarachnoid clots 
larger than 5 x 3mm or layers of blood ≥1 mm in vertical cisterns and fissures.  
Conversely, vasospasm was extremely rare in patients without subarachnoid 
blood.  This system was based on CT imaging performed in the 1970s with 16 
mm slices.  Two slices with blood within vertical cisterns implied at least a 
thickness of 8 mm.  On three slices, this will imply at least a thickness of 32 
mm.  Although a widely used classification in modern practice, it’s reliance on 
this out-dated method has led to further validation.  The findings were 
confirmed in a study demonstrating that thick subarachnoid clot completely 
filling any cistern/fissure was an independent predictor of DIND4.  
Intraventricular haemorrhage had similar predictive value. 	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Management of aSAH 
 
Although trauma is the most common cause of SAH, aSAH accounts for 
approximately 85% of all cases of spontaneous SAH26.  The remainder of 
cases are often due to non-aneurysmal ‘perimesencephalic’ SAH or other rare 
causes.  Clinical features consist of a spectrum ranging from a sudden onset 
headache to sudden death.  Apart from altered consciousness, other 
associated features include vomiting, signs of meningism and seizures.   
 
Investigation is based on clinical assessment followed by computerised 
tomography (CT) of the brain.  In approximately 3% of patients presenting 
with clinical features of aSAH with a normal CT scan of the brain, examination 
of the cerebrospinal fluid (CSF) within 12 hours of the haemorrhage can 
reveal metabolites of haemoglobin such as bilirubin indicating a haemorrhagic 
event within this time frame26.  All such patients should undergo further 
diagnostic imaging to confirm or exclude the presence of an aneurysm.  The 
current gold standard remains four-vessel digital subtraction angiography 
although the sensitivity and availability of other imaging modalities such as 
CT-angiogram is improving26,27. 
 
Once diagnosis of aSAH is confirmed the aims of treatment are airway, 
ventilation and haemodynamic stabilisation followed by correction of 
reversible causes of neurological deterioration.  This includes surgical 
evacuation of intracerebral haemorrhagic extensions of the SAH or correction 
of hydrocephalus.  The former is seen in approximately one third of patients 
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although surgical evacuation is usually reserved for those haematomas that 
exert significant mass effect26.  Patients with intraventricular and intracerebral 
haemorrhagic extensions are more likely to develop hydrocephalus.  They 
may develop a gradual deterioration in conscious level following the 
haemorrhagic ictus or may initially present with an altered conscious level and 
ventriculomegaly.  Approximately 20% of patients with aSAH will demonstrate 
ventriculomegaly on initial CT and approximately 80% of these patients will 
also have impaired consciousness28.  Untreated however, within 24 hours 
around half of these patients will show spontaneous improvements in 
consciousness26,28.  Treatment of hydrocephalus (symptomatic 
ventriculomegaly) usually involves continuous external ventricular drainage 
aimed at maintaining normal ventricular pressure.  	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Management of ruptured cerebral aneurysms 
 
Subsequent management consists of early definitive aneurysm treatment 
followed by supportive measures to reduce the incidence and severity of 
complications.  Within a few hours following haemorrhage, 15% of patients 
demonstrate a sudden deterioration in consciousness consistent with re-
bleeding from the unprotected aneurysm26.  Although pre-hospital re-bleeding 
has not been extensively studied, a recent prospective study has 
demonstrated that the greatest risk of re-bleeding is in the immediate few 
hours following haemorrhage29.  For the continued course of patients 
surviving the first day following haemorrhage, the overall cumulative risk of re-
bleeding at one month is 40% without treatment26.  Re-bleeding is associated 
with a poorer clinical grade of haemorrhage and poorer outcome.  An earlier 
study has demonstrated that a poor outcome was secondary to the initial 
haemorrhage in 32% of cases and secondary to a re-bleed in 35% of cases30.  
No specific risk factors for re-bleeding have been clearly demonstrated31.  
 
Traditional aneurysm treatment consists of craniotomy and surgical clipping.  
Endovascular occlusion of the aneurysm using detachable coils has emerged 
as a less invasive alternative treatment.  Although there have been numerous 
observational studies, a large multi-centre randomised controlled trial 
comparing the two forms of treatment closed recruitment following an interim 
analysis which revealed a benefit of endovascular treatment32.  The inclusion 
criteria for this trial included aSAH with the intention of aneurysmal treatment 
by surgical or endovascular means.  Other criteria included a ruptured 
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aneurysm that was amenable to both endovascular and surgical treatment 
and an aneurysm that was not already clearly appropriate for one modality of 
treatment.  There was recruitment of 2143 patients from 42 centres who were 
randomised into either the endovascular group (n=1073) or the surgical group 
(n=1070).  Most patients were in a good clinical state with a small aneurysm 
of the anterior circulation.  The relative and absolute risk reduction in the 
primary outcome measure of death or dependence at one year (Modified 
Rankin Score (MRS) of 3-6, see appendix 1.5) of endovascular versus 
surgical treatment was 22.6% and 6.9% respectively.  A further analysis of 
these results has demonstrated that this early survival advantage was 
maintained for 7 years33.  The analysis showed no good evidence that the 
benefit of endovascular surgery does not apply across all sub-groups (age, 
World Federation of Neurological Surgeons (WFNS) grade, Fisher grade and 
size and location of aneurysm).  However for age, WFNS grade and 
aneurysm location, treatment effects were heterogeneous and difficult to 
interpret.  The risk of late re-bleeding is low in both groups, although higher in 
the endovascular group. 
 
The main criticisms of this trial include an expertise bias in favour of 
endovascular treatment.  Most endovascular centres contributing to the trial 
employed dedicated interventional radiologists whereas contributions to the 
surgical arm were mainly from centres with general neurosurgeons without a 
specific neurovascular interest34.  Secondly, a sample bias resulted in a 
propensity for smaller aneurysms to be included (92% less than 10 mm, 50% 
less than 5 mm) and an under-representation of middle cerebral and posterior 
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circulation aneurysms.  This bias is in favour of endovascular treatment since 
large aneurysms and those of the middle cerebral aneurysm are anatomically 
more difficult to treat with this modality.  However, the size and location of 
these aneurysms may represent the actual size and location of aneurysms 
seen in Europe35.  Anterior circulation aneurysms do make up 90% of those 
encountered.  In the UK, 85% of aneurysms are less than 1 cm and 66% are 
less than 5 mm35.  A large number of patients eligible for the trial (9559 
patients) were excluded by the treating physician.  In the majority of these 
cases, the treating surgeon felt that surgery was the most appropriate form of 
treatment.  As a result, patients in this trial are only included after they have 
satisfied this inclusion criteria and thus is not a true randomisation and does 
not represent an intention-to-treat randomised trial. 
 
In summary, this trial is an important step in defining the roles of endovascular 
and microvascular surgery in the treatment of ruptured cerebral aneurysms 
although optimal management for groups of patients is still to be clearly 
defined.  
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Investigating DIND 
The gold standard for the diagnosis of angiographic vasospasm has been 
accepted as arterial narrowing documented on digital subtraction angiography 
(DSA)36.  Transcranial doppler (TCD) has been utilised as a surrogate 
measure of angiographic vasospasm with reasonable specificity and 
sensitivity but variable prediction of clinical deterioration/DIND37,38.  The 
clinical entity of DIND better correlates with outcome and does not necessarily 
co-exist with angiographic vasospasm.  The diagnostic criteria do vary slightly 
throughout the literature but it is in essence a diagnosis of exclusion and 
consists of two components.  The first is often defined as a decrease in 
consciousness and/or new focal neurological deficit seen at least three days 
post ictus following exclusion of other causes of such a neurological 
deterioration (commonly re-bleed, seizure, hydrocephalus, hypoxia, sepsis 
and electrolyte disturbances).  The second component is the presence of a 
new infarct not present on the initial and immediate post-operative imaging.  
Part of the variation in the diagnostic criteria seen in the literature is due to the 
requirement (or not) of angiographic vasospasm (or a surrogate measure of 
this from TCD) in diagnosing DIND.  Computerised tomography angiogram 
(CT-A) and computerised tomography perfusion (CT-P) are increasingly being 
utilised to assess angiographic vasospasm (including distal microvascular 
vasospasm) and brain perfusion but are yet to be established as gold 
standards39. 
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Management of DIND 
 
At present, the mainstay of DIND treatment is neurocritical care management 
aimed at reducing secondary brain injury, oral nimodipine, haemodynamic 
therapy and endovascular techniques to improve angiographic vasospasm.  
What follows is an overview of the evidence underlying current therapy.  
Although statin/magnesium/nicardipine therapy and cerebrospinal fluid (CSF) 
drainage are not widely used, their inclusion herein is justified by recent 
studies highlighting their merit. 
 
Haemodynamic therapy 	  
Denny-Brown first noted that hypotension was associated with neurological 
deficits in patients with severe structural narrowing of cerebral blood 
vessels40.  It was not until the 1960s and 70s that attempts at increasing 
systolic blood pressure with plasma expanders and vasopressors were noted 
to reverse ischaemia-related symptoms in cerebrovascular insufficiency41.  In 
this regard, Kosnik and Hunt described the use of induced hypertension and 
hypervolaemia to reverse established DIND42.  Larger series have shown that 
approximately two-thirds of patients with DIND improve with haemodynamic 
therapy, with the remaining patients either unchanged or worse despite 
maximal medical therapy43,44.  Similar results were noted when induced 
hypertensive therapy was used alone45.  This benefit may be seen following 
increases in cardiac index in addition to mean arterial pressure (MAP)46.   
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The physiological explanation is that cerebral vasospasm results in a shift of 
cerebrovascular resistance to the large vessels of the Circle of Willis, thus 
impairing autoregulation in the distribution of the vasospastic vessel.  
Consequently, CBF varies directly with systemic blood pressure and 
according to the Hagen-Poiseuille law, increasing perfusion pressure or 
decreasing viscosity increases CBF.  Although haemodynamic therapy has 
become widely accepted in the management of DIND, there are few published 
controlled trials investigating its efficacy and variable administration to 
patients, despite its association with significant morbidity: fluid overload (10-
40%), pulmonary oedema (2-34%), dilutional hyponatraemia (3%), congestive 
heart failure (5-20%) and myocardial infarction (2%)47.  Other complications 
include intracranial haemorrhage (less common with early aneurysm 
treatment), global cerebral oedema and death.   
 
It is unclear which component of haemodynamic therapy (hypertension, 
hypervolaemia or haemodilution) confers benefit. The most contentious is 
haemodilution, following reports of reduced brain oxygen supply despite 
adequate CBF48.  Isovolaemic haemodilution (haematocrit target of 0.28) has 
been shown to increase ischaemic brain volume despite a global increase in 
CBF49.  Unfavourable outcome was associated with lower haemoglobin 
concentrations over the first two weeks following haemorrhage50.  Conversely, 
higher haemoglobin levels have been associated with a better outcome 
following aSAH51.  Similar questions have been raised regarding the 
additional benefit of hypervolaemic therapy46,47,49, partly because of the 
increased risk of pulmonary oedema.  There is an association between the 
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use of synthetic rescue colloids and impaired cerebrovascular parameters in 
poor WFNS grade patients, as well as poor outcome in all aSAH patients52.  
These findings are supported by other studies demonstrating that although 
induction of hypertension alone following aSAH increases regional CBF and 
brain oxygenation, additional hypervolaemic and haemodilutional therapy 
confers no additional benefit53,54.  A systematic review of the literature 
concluded that there is no good evidence from controlled studies for a positive 
effect of triple-H or its components on CBF in aSAH patients54.  Thus, there is 
a need for a carefully devised study utilising multimodal monitoring to 
investigate the effects of hypertensive therapy in hyper- and isovolaemic 
states without a concomitant decrease in haematocrit.  The morbidity 
associated with such therapy needs further clarification.   
 
Similar uncertainties are noted for the use of prophylactic haemodynamic 
therapy following aSAH.  In a recent systematic review of 49 trials in which 
this therapy was administered prophylactically, only four were prospective, 
controlled and comparative studies55.  Of these, three were not 
sufficiently/appropriately controlled or comparative to assess the efficacy of 
this therapy.  However, two recent studies randomly assigned normovolaemic 
or hypervolaemic therapy to patients and reported no difference in the 
incidence of DIND between groups56,57.  This may be explained by the 
observation that although hypervolaemic therapy results in higher daily fluid 
intake and cardiac filling pressures, it has no effect on net fluid balance, blood 
volume or CBF as assessed by 133Xenon clearance57.  Thus, earlier studies 
demonstrating improvements in CBF may have done so in initially 
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hypovolaemic patients given prophylactic hypervolaemic therapy soon after 
haemorrhage.  This is almost certainly the case in studies prior to 1985, when 
fluid restriction was common practice57. 
 
Oral nimodipine 	  
Numerous trials have investigated the use of oral nimodipine prospectively.  
The largest and most widely quoted of these (the British aneurysm nimodipine 
trial) recruited 554 patients to receive either placebo or 60 mg of nimodipine 
four hourly for 21 days58.  There was a relative reduction in the incidence of 
cerebral infarction and poor outcome in the treatment group by 34 and 40%, 
respectively.  Furthermore, a meta-analysis of seven nimodipine trials 
demonstrated that nimodipine almost halved the risk of neurological deficit 
and/or death secondary to vasospasm59.  The incidence of infarction was also 
reduced by almost 60%, although mortality rate was largely unaffected.  The 
suggestion that oral nimodipine is of clinical benefit in this setting was echoed 
by another meta-analysis and a recent Cochrane review of trials investigating 
several calcium antagonists60,61.   
 
Although oral nimodipine is accepted as standard care, its precise mechanism 
of action remains unclear.  Despite being shown to reduce the incidence of 
DIND and infarction in clinical trials, it has negligible effects on angiographic 
vasospasm; indeed, nimodipine has been shown to improve behavioural 
outcomes in a murine SAH model without changing blood vessel diameter62.  
Treatment with nimodipine (which acts on the cerebral vasculature rather than 
at the neuronal level) resulted in worsening outcome despite increased blood 
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vessel luminal diameter.  This suggests that nimodipine may be 
neuroprotective by blocking calcium influx at a neuronal level.  A possible 
explanation for its limited effectiveness on angiographic vasospasm may 
relate to its predilection for small perforating arterioles rather than large 
proximal vessels: nimodipine results in greater vasodilatation of isolated rat 
intra-cerebral penetrating arterioles compared to pial arterioles.  In a rat model 
of focal cerebral ischaemia, nimodipine reduced infarct size and both necrotic 
and apoptotic cell death63.  It was also shown to antagonise spreading 
ischaemia induced by red blood cells in rats64.  Its use in aSAH patients has 
been associated with an increase in fibrinolytic activity65.  On balance, 
nimodipine’s success in reducing the incidence of DIND in the clinical setting 
compared to its failure to improve outcome following ischaemic stroke may be 
reflective of the window of opportunity for preventing these cellular processes 
from taking place between aSAH ictus and the onset of DIND62.   
 
Endovascular therapy 	  
Endovascular therapies for vasospasm have evolved since the first report of 
balloon catheter usage66.  For patients with severe angiographic vasospasm 
and DIND that is refractory to haemodynamic therapy, the use of both 
endovascular balloon techniques and intra-arterial infusion of pharmacological 
vasodilators has become widespread.  Research in this field consists largely 
of retrospective studies assessing the safety and efficacy of these techniques, 
with no randomised controlled trial to assess their impact on neurological 
outcome.  For transluminal balloon angioplasty (TBA), several case series 
have reported angiographic improvements as high as 100%67.  Overall 
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neurological improvement and incidence of infarction, however, has been 
modest67-69.  Pharmacological agents such as papaverine were initially 
administered with fervour in an attempt to treat previously inaccessible distal 
vascular segments.  However, criticism of its short active half-life, deleterious 
side effects (increasing intracranial pressure, which may depress capillary 
perfusion and venous outflow at the microcirculatory level70) and modest 
improvement in neurological outcome has kerbed this enthusiasm.  A recent 
phase II randomised trial suggests that prophylactic TBA prior to the onset of 
DIND may reduce its incidence, although this study was inadequately 
powered to comment on the significance of this difference71.   
 
Intra-arterial nimodipine administration is gaining some acceptance in DIND 
management.  Although the first descriptive studies gave mixed results about 
its effectiveness in treating both angiographic vasospasm and DIND, recent 
studies have demonstrated clinical improvements in approximately 75% of 
patients, although its effect on angiographic vasospasm (the primary 
endpoint) remained unclear72-74.  A recent small, prospective study has 
contradicted these findings75.  Although mean transit time and selective time 
to peak of the brain parenchyma were reduced one day after treatment, this 
effect was not sustained.  Effects on CBF and volume were even less 
apparent.  Half of assessable patients were clinically unchanged and 20% 
worsened following intervention.  However, a third of patients failed to 
demonstrate angiographic improvements following the first treatment and 
were therefore excluded from further intervention despite the evidence that 
nimodipine may be beneficial without altering vessel diameter.  In order to 
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counteract the problem of short duration of action, continuous intra-arterial 
infusion of nimodipine may represent a promising mode of delivery76,77.  There 
is evidence to suggest that recurrent angiographic vasospasm and DIND is 
less frequently seen following intraarterial nimodipine when combined with 
TBA78.  Future prospective studies to evaluate the effects of intra-arterial 
nimodipine should therefore be adequately powered to detect changes in 
clinical symptoms and outcome rather than angiographic vasospasm, and 
should also be carefully separated from other concurrent endovascular 
modalities.  
 
Nicardipine 	  
Nicardipine prolonged-release implants (NPRIs) have been subject to 
investigation in this setting79,80.  Consecutive patients with aSAH implanted 
with NPRIs were shown to have a reduced incidence of angiographic 
vasospasm and DIND (11% in control group vs 6% in treated group)79.  This 
was not a randomised study and was too small to comment on clinical 
differences.  A small double-blinded randomised controlled trial which was not 
powered to detect changes in clinical outcome did demonstrate a significant 
reduction in delayed ischaemic lesions not attributable to operative morbidity 
in the study group given NPRIs80.  Lower incidence of poor outcome and 
death were also noted in the treated group.  This did not result in an improved 
quality of life at one year81.  The use of nicardipine pellets or any drug infused 
via implants relies on placement during surgical aneurysm treatment.  With 
the increasing trend towards endovascular treatment of ruptured aneurysms, 
future studies investigating such implants need to be devised with this in 
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consideration.  The additional morbidity associated with application of these 
implants in those not undergoing surgical treatment of the aneurysm will have 
important implications on their potential role in the future.   
 
Statin therapy 	  
There has been much interest in 3-hydroxy-3-methylglutaryl coenzyme A 
(HMGCoA) reductase inhibitors in the management of aSAH.  These 
compounds are potent inhibitors of cholesterol production, although evidence 
suggests that statin therapy can also improve endothelial function and 
upregulate endothelial nitric oxide synthase (eNOS) without altering serum 
cholesterol levels.  Other beneficial properties of statins include inhibition of 
platelet aggregration/adhesion, anti-inflammatory effects and decreased 
oxidative stress.  Prospective randomised studies investigating the use of 
statins following aSAH have given promising results82-84, with simvastatin and 
pravastatin reducing the incidence of DIND by 60-80%.   
 
However, although these studies were blinded, they were inadequately 
powered to detect changes in clinical endpoints.  The 60% incidence of DIND 
in the placebo group of the Lynch study is substantially higher than that 
documented in the literature.  Less than 50% of patients completed the 
treatment in the Tseng study, although results were analysed as intention-to-
treat.  In a recent study comparing outcome before and after the introduction 
of statin therapy, no statistically significant difference in the incidence of DIND 
or poor outcome was found85.  Although this study was retrospective in design 
and spanned a time period when endovascular aneurysm treatment was 
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being introduced, the study groups were similar and this represents the 
largest clinical investigation of statin use following aSAH to date.  Other 
smaller studies have noted similar results86,87.  Recent meta-analyses of this 
data have given mixed opinions regarding the benefits of statins in this 
setting, although there is a unified call for a prospective, randomised and 
controlled trial to investigate this further88-90 as the detectable clinical 
differences may be far smaller than those noted in the current prospective 
studies.  The results from such a trial are awaited (www.stashtrial.com). 
 
There have been mixed reports of the effects of long-term statin use prior to 
haemorrhage.  Evidence for its benefit comes from two retrospective reports 
demonstrating an association between statin therapy and a reduction in the 
incidence of DIND and improved outcome91,92.  However, continuity of therapy 
following admission was not clearly discussed and the Parra study lacked 
complete three-month outcome data.  Evidence against the beneficial effects 
of statins consists of two larger retrospective studies demonstrating no 
association with DIND and an increase in angiographic vasospasm risk in 
those patients receiving statin therapy93,94.  Many statin users had their 
medication discontinued on admission in both studies, which may have 
impacted on the results given that the effect of pre-haemorrhage use of 
statins on the subsequent course of the haemorrhage and outcome remains 
unclear. 
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Magnesium 	  
Magnesium sulphate acts as a non-competitive antagonist of voltage-
dependant calcium channels and has been shown to have a neuroprotective 
effect by reducing vasospasm and infarct volume after experimental SAH.  
Hypomagnesaemia occurs in more than half of patients with aSAH and is 
associated with bleed severity95 and, following ictus, is predictive of DIND.  
Treatment of aSAH patients with a continuous infusion of magnesium 
sulphate was associated with a 34% reduction in DIND risk and a better 
outcome96.  A significant benefit was noted in delayed ischaemic infarction97.  
A recent Cochrane review of randomised trials investigating magnesium use 
in addition to oral nimodipine concluded that this represents a promising 
intervention that requires further investigation with a larger trial.  Results from 
such a trial are awaited98. 
 
CSF drainage and thrombolysis 	  
Since thick subarachnoid clot completely filling any cistern or fissure has been 
shown to be an independent predictor of DIND, it follows that clearance of 
blood from the subarachnoid space may reduce the prevalence and severity 
of DIND.  The reported benefits of CSF drainage and thrombolysis in this 
setting will be discussed in the first part of this thesis.  	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Pathophysiology of delayed ischaemic neurological 
deficit 
 
Although current therapies have improved the prognosis in patients with 
DIND, outcome remains poor.  Interventions such as TBA and endothelin 
antagonists effectively target angiographic vasospasm but fail to improve 
outcome, lending notion to the theory that angiographic vasospasm may be a 
parallel end-point to the pathological process that results in ischaemic injury.  
Thus, the relationship between angiographic vasospasm and neurological 
outcome may be associative rather than causative, and neurological injury 
may not be entirely explained by ischaemia.  However, it must be emphasised 
that this is a theory and that angiographic vasospasm will probably play some 
part in DIND.  Some patients do respond to angioplasty and other patients 
with significant angiographic vasospasm do develop ischaemia and infarction 
in this distribution and their outcome is poor.  New lines of research are 
therefore redefining our understanding of this process.  What follows is a 
discussion of the current evidence for the pathophysiology of DIND.   
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Nitric oxide 	  
Nitric oxide (NO) is a ubiquitous, inorganic and membrane-permeant gas 
produced by endothelial cells, neurons, glia and macrophages by three 
isoforms of nitric oxide synthase (NOS)99.  Cerebrovascular tone requires 
continuous endothelial cell NO release100 which, under physiological 
conditions, is produced by constitutive eNOS and neuronal NOS (nNOS).  
Paradoxically, NO has both neuroprotective and cytotoxic effects in the 
central nervous system (CNS). The relatively low levels of NO produced by 
eNOS are neuroprotective, whereas high levels of NO produced by 
macrophage nNOS and induced NOS (iNOS) during ischaemia may 
exacerbate/contribute to injury99.   
 
Much of the research investigating NO in aSAH has been based on animal 
models and has concentrated on association with angiographic vasospasm.  It 
has been postulated that oxyhaemoglobin found in abundance in the 
perivascular space following aSAH, can scavenge NO and destroy nNOS-
containing neurons101.  Several clinical studies have reported conflicting 
findings of CSF nitrate (a stable NO metabolite) elevation or depression 
following aSAH99,100,102.  Sustained overproduction of NO can lead to 
membrane peroxidative injury, change in blood vessel morphology and 
endothelial dysfunction.  However, neuronal injury secondary to ischaemia 
can also produce NO, and so it is unclear as to whether NO is a cause or a 
consequence of DIND, or both100.  Indeed, much of the research that has 
concentrated on endothelial cell dysfunction and associated mediators has yet 
to determine whether endothelial cell dysfunction is a true pathophysiological 
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factor in angiographic vasospasm and DIND or just an epiphenomenon.  
Although NO donors such as sodium nitroprusside have been successful in 
treating vasospasm in animal models, they have not consistently shown 
promise in clinical studies and are potentially limited by side-effects103,104.  
Newer modalities of NO donation should be subject to future investigation105.   
 
Endothelin 	  
Endothelin-1 (ET-1) is a molecule produced principally by the endothelium 
which acts at a paracrine level to promote smooth muscle contraction, 
vasoconstriction, endothelial/smooth muscle cell proliferation and 
inflammation106.  Several human studies have demonstrated elevated levels 
of ET-1 in plasma, CSF and microdialysate following aSAH107-109.  However, 
there have been conflicting results as to which compartment this elevation is 
observed in, and its precise relationship with angiographic vasospasm.  More 
importantly, the association between levels of ET-1 and DIND has been 
demonstrably weak.  A randomised, double-blind, placebo-controlled trial 
investigated the use of clazosentan, a selective ET-A receptor antagonist, 
following aSAH demonstrated a significant dose-dependent reduction in the 
primary end-point of moderate to severe angiographic vasospasm in patients 
randomised to the treatment arm110.  However, this did not translate into 
improved clinical outcome and was associated with an increased incidence of 
pulmonary oedema, adult respiratory distress syndrome and hypotension.  
Centrally assessed post-analysis of this data did demonstrate a trend towards 
improved outcome when DIND with mild angiographic vasospasm was 
excluded. 
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Lipid peroxidation 	  
Accumulation of arachidonic acid may result in alterations in vasomotor 
regulation and disruption of blood brain barrier (BBB) integrity111.  
Haemoglobin breakdown products may activate lipooxygenase and 
cyclooxygenase, thus promoting conversion of arachidonic acid into products 
such as prostaglandins and leukotrienes.  Levels of lipid peroxides were 
significantly higher in the CSF of aSAH patients with DIND than those without 
and were noted prior to the development of cerebral infarction. As such, these 
are more likely to have been produced by the blood clot rather than the 
infarction per se112.  Efflux of free fatty acids is a marker of lipid peroxidation.  
CSF free fatty acid levels have been noted to undergo a biphasic increase 
after aSAH111, with patients with DIND having higher CSF concentrations of 
arachidonic, palmitic and linoleic acid.   
 
The arguments in favour of lipid peroxidation playing a role in the 
pathogenesis of DIND are attractive.  Oxyhaemoglobin may catalyse free 
radical generation and lipid peroxidation, resulting in membrane perturbation 
and cellular dysfunction within the arterial wall.  Lack of effective scavenger 
systems within CSF may account for the delayed nature of the deficits since 
systems originating in serum may suppress free radical reactions within three 
days of haemorrhage112.  In addition, lipid peroxidation may directly stimulate 
smooth muscle contraction and generate an inflammatory response involving 
arachidonic acid metabolites111.  Five multicentre randomised controlled trials 
have investigated the use of tirilazad, an inhibitor of lipid peroxidation, a 
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recent meta-analysis of which has shown that although tirilazad treatment was 
associated with a significant reduction in the incidence of DIND, overall 
outcome was unchanged113,114.  
 
Bilirubin oxidative products (BOXes)  
In terms of oxidative stress, there has also been interest in free radical 
oxidation of bilirubin, biliverdin and haem to produce BOXes115,116.  
Interestingly, the formation of bilirubin and subsequent oxidation to BOXes 
results in a peak concentration of the latter which coincides with the peak 
period of angiographic vasospasm and DIND116.  Cerebrospinal fluid from 
aSAH patients with angiographic vasospasm (with and without DIND) features 
higher levels of bilirubin, oxidative stress and BOXes than that of non-
vasospasm patients117.  Unfortunately, the emphasis of much of this elegant 
work has been on in vitro studies and angiographic vasospasm.  BOXes 
applied to the brain surface of male Sprague Dawley rats led to a dose-
dependent arteriolar vasospasm without any evidence of infarction118.  This 
discrepancy was thought to be due to the single application of BOXes as 
opposed to prolonged exposure in the clinical setting or the possibility of other 
factors involved in the development of DIND and infarction116.  Either way, 
further human studies are required to determine and compare the oxidative 
stress status and the level of BOXes in both DIND and non-DIND patients.  
 
Microcirculation and autoregulation 	  
It has been demonstrated that regional CBF is only affected once 
extraparenchymal vasospasm results in >50% luminal narrowing119. Although 
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large cerebral vessels contribute to vascular resistance, they do not 
significantly affect CBF120.  A major determinant of microvascular pressure is 
the ratio of upstream to downstream resistance121.  If large arteries constrict 
and arterioles dilate, there will be a decrease in microvascular pressure 
without a change in CBF, making microvascular pressure an independently 
regulated variable and contradicting the concept that large vessel vasospasm 
contributes significantly to downstream disturbances of CBF.  Although severe 
extraparenchymal vasospasm is associated with reduced CBF, both reduced 
CBF and DIND are noted even with mild vasospasm or no vasospasm at all 
(i.e. severe vasospasm is not a prerequisite for DIND)119,122,123.  Other 
sources of evidence against large vessel vasospasm as a significant cause of 
ischaemia and neurological deficit include several studies demonstrating a 
poor correlation between the site and severity of angiographic vasospasm and 
the clinical/measured ischaemia119,120.  The location of cerebral infarction on 
CT could not be predicted by angiographic vasospasm in up to one-third of 
cases124, although formal angiography was not performed in all patients.  
Post-mortem studies have demonstrated that most infarcts following aSAH do 
not have the typical appearance of large territorial infarcts and are cortical in 
>75% of aSAH patients125.  Widespread and hypothalamic lesions consistent 
with those secondary to diffuse microangiopathy were noted in a subset of 
patients.  Cortical lesions were associated with fluctuating blood pressure 
suggesting autoregulatory dysfunction.  A direct effect of blood clot around the 
cortex has also been implicated with cortical infarcts126.   
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These observations that there may be other factors contributing to ischaemia 
have prompted increasing interest in cerebral microvasculature and 
autoregulatory function.  The evidence to suggest that vasospasm can occur 
at a microvascular level is based largely on animal models and has given 
conflicting views, although a clinical study has demonstrated a strong inverse 
correlation of peripheral cerebral circulation time (a measure of microvascular 
resistance) and regional CBF regardless of the severity of angiographic 
vasospasm by digital subtraction angiography119.   
 
Initial reports indicate that reduced autoregulatory responses to carbon 
dioxide are not due to autoregulatory capacity dysfunction, but may instead be 
due to maximal dilatation of peripheral arterioles in an attempt to maintain 
CBF when cerebral perfusion pressure (CPP) is reduced48,119.  More recent 
positron emission tomographic (PET) studies have demonstrated a reduction 
in cerebral blood volume (CBV) implicating impairment of the vasodilatory 
capacity of distal vessels in the face of reductions in CPP127.  It was 
concluded that since a reduction in CBV was noted in areas of angiographic 
vasospasm under hypoxic conditions that would normally increase CBV, then 
parenchymal vessels distal to arteries demonstrating vasospasm exhibited 
impaired autoregulatory dilation.  This opinion has been echoed by other 
studies measuring autoregulation by different techniques128-130.  For example, 
a recent study utilised brain tissue oxygen (PtiO2) and pressure reactivity as a 
surrogate measure of autoregulation to demonstrate impairment of 
autoregulatory capacity in aSAH patients with DIND several days prior to the 
onset of ischaemic changes128.  It is thought that perturbed cerebral 
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vasculature autoregulatory function fails to compensate for vasospasm-
induced reductions in vessel diameter at the microvascular level, thereby 
increasing the risk of ischaemia128.  This is probably an oversimplification of a 
complex process, highlighted by the wide variation in CBF patterns amongst 
patients with DIND, which range from reduced flow to hyperaemia on PET 
images131.   
 
Although current evidence points to autoregulatory dysfunction in DIND, more 
clarity is required regarding the extent of this dysfunction and the regions at 
risk.  Whether this represents new autoregulatory dysfunction at the time 
of/immediately preceding DIND or a failure to re-establish autoregulation after 
the haemorrhage ictus is still unclear.  New clinical modalities including real-
time local CBF monitors used in conjunction with other local and global 
monitoring tools may help improve our understanding of microcirculation.  
These findings would clearly need to be considered in context with cerebral 
metabolism and oxygenation. 
 
Microthrombosis  	  
There has been increasing interest in the role of platelets and the coagulation 
system in DIND.  Platelet aggregation is thought to impede circulation and 
aggravate brain injury in addition to causing scattered microinfarcts132.  This is 
supported by human post-mortem studies following aSAH which have 
demonstrated the presence of infarcts with the appearance of those 
secondary to small thomboemboli120.  Other possible mechanisms of injury 
resulting from platelet aggregation include release of vasoactive contents from 
 45	  
granules and alterations in microvascular structure following release of 
enzymes133.  While an increase in platelet consumption in the days following 
aSAH was shown to be an independent predictor of DIND in an Asian 
population134, these findings were not seen in a Caucasian population135, 
although both studies lacked assessment of platelet function.  A recent meta-
analysis of seven trials investigating anti-platelet therapy following aSAH 
concluded that this treatment may reduce the risk of ischaemic complications 
and improve outcome, although these findings were not statistically 
significant136.   
 
Aneurysmal SAH has nevertheless been associated with a hypercoagulable 
state134,137-139.  Markers of thrombin production and fibrinolytic activity were 
significantly raised and correlated with grade of aSAH and long term 
outcome137-139, although this correlation was less apparent in a larger study 140 
and no association has been found between these markers and 
DIND/cerebral infarction137,139,141.  There have been conflicting reports as to 
whether D-dimer is an independent predictor of DIND138,141.  Although 
uncertainty exists regarding CSF markers of fibrinolysis since most studies 
had been performed in conjunction with antifibrinolytic therapy, a recent study 
has demonstrated an association between CSF thrombin activation and 
infarction secondary to DIND142.  Only the rate of blood clearance in the first 
three days following aSAH could predict DIND.  Higher levels of thrombin 
activation were noted in patients with low blood clearance and in those with 
DIND.  This raises the question as to whether the compartmentalised CNS 
coagulation cascade exerts its primary effect by slowing blood clearance and 
 46	  
allowing other factors to trigger DIND rather than by a direct thrombotic effect 
per se. 
 
Inflammation and Complement 	  
There is increasing evidence to suggest that a complex inflammatory 
response is initiated both systemically and within the CNS following aSAH.  
How this relates to ischaemic neurological injury and which exact mediators 
and mechanisms are involved is currently unclear.  A detailed review of this 
subject is presented in part 2 of this thesis. 
 
Apoptosis 
Endothelial cell apoptosis has been implicated in breakdown of the BBB, 
oedema formation and secondary brain injury following aSAH143.  A key event 
in this process is thought to involve apoptosis of neurons and cerebral 
endothelial cells.  Neuronal cell death contributes to cytotoxic oedema while 
endothelial cell apoptosis is thought to result in a breakdown of the BBB, 
which subsequently contributes to vasogenic oedema.   
 
Although experimental data is drawn principally from animal models (which 
operate on a different timescale to that seen in humans) following SAH, it has 
repeatedly been shown that the apoptotic apparatus is activated following 
SAH143-147 (Table 1).  While p53 is a transcription factor that has been 
implicated in the pathogenesis of neoplastic disease, there is evidence to 
suggest that it also plays a role in the apoptotic process following aSAH via 
caspase-dependent and independent pathways144.  Both p53 and pan-
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caspase inhibition attenuate apoptotic activation and, more importantly, 
reduce delayed (>24 h) BBB breakdown and increases in brain water content.  
Neurological outcome has also been shown to improve in most models.  
However, because of the broad mechanism of action of p53 and the 
complexity of the caspase-dependent and independent pathways, further 
information is required regarding the type and extent of inhibition required to 
induce these responses.  Future clinical studies investigating apoptotic 
activation following aSAH may well underpin the development of new 
therapeutic strategies. 
 
Spreading Depolarisation 	  
Cortical spreading depolarisation (CSD) was first described in rabbit cerebral 
cortex148 and refers to the wave of neuronal depolarisation which is ignited 
when passive cation influx across cell membranes exceeds adenosine tri-
phosphate (ATP)-dependant sodium and calcium pump activity, which if 
prolonged can result in cell death149.  Since under physiological conditions 
pump recruitment occurs, this is an energy consuming process.  As a result, 
CSD induces vasodilation causing an increase in CBF.  However, under 
ischaemic conditions, CSD can exacerbate ischaemia by causing severe 
microvascular vasoconstriction and reduced CBF150.  This cortical spreading 
ischaemia (CSI) describes this CSD-induced perfusion deficit149. 
Table 1-Summary of experimental evidence investigating apoptotic pathways following SAH 
Abbreviations: SAH-subarachnoid haemorrhage, TUNEL- Terminal deoxynucleotidyl transferase dUTP nick end labeling, BBB-blood brain barrier, TNF-
tumour necrosis factor, IL-interleukin, BA-basilar artery, Bcl-B-cell lymphoma, bax-Bcl-2 associated X-protein. 
Study 
Author 
Model Utilised Apoptotic 
inhibition 
Main findings (Effect of inhibition) Effect on neurological scores/brain 
oedema/mortality 
Park et al., 
2004 
Sprague-Dawley rat 
SAH model.  
Pan-caspase 
inhibition. 
1. No change in caspase-3 and TUNEL staining in 
hippocampus and cortex but attenuation in endothelial cells. 
2. Attenuation of vasospasm in blood vessels. 
No significant difference in mortality. 
Improvement in BBB permeability, brain water 
content and neurological score after 24 hours 
in treated group. 
Zhou et al., 
2005 
Mongrel dog double 
SAH model.  
p53 inhibition. 1. Attenuation of angiographic and histological vasospasm. 2. 
Significantly reduced expression of all apoptotic proteins. 3. 
Reduced expression of TNF-α in endothelial and smooth 
muscle cells. 
Delayed improvement in appetite and activity 
in the treated group. 
Cahill et al., 
2006 
Sprague-Dawley rat 
SAH model.  
p53 inhibition. 1. Attenuation of increased expression of all apoptotic 
mediators, particularly p53. 2. Attenuation of severe BA 
vasospasm at 24 and 72 hours.  
Improved mortality and neurological scores at 
72 hours. BBB function and brain water 
content improved at 24 hours only, effects had 
subsided by 72 hours. 
Iseda et al., 
2007 
New Zealand white 
rabbit and Sprague-
Dawley rat SAH models. 
Pan-caspase 
inhibition. 
1. Reduced angiographic/histological vasospasm. 2 Reduced 
CSF IL-1β. 3. Reduced caspase-1/IL-1β immunoreactivity in 
infiltrating macrophages in the subarachnoid space. 
Not commented upon. 
Gao et al., 
2008 
Sprague-Dawley rat 
SAH model.  
Pan-caspase 
inhibition 
(tetramethylpyrazin
e) 
1. Attenuation of p53 and TUNEL staining in cerebral cells. 2. 
Attenuation of histological vasospasm. 3. Reduced protein 
levels of Bcl-2, bax and caspase-3 in hippocampus and basal 
cortex. 
Improvement in neurological function, brain 
water content and BBB permeability at 24 
hours in treated group. 
Animal studies have demonstrated that topical brain superfusion of artificial 
CSF with a high concentration of haemoglobin and potassium resulted in 
acute, spreading decreases in CBF151, which transformed a normal spreading 
hyperaemic response into a CSI152.  This pattern of ischaemia was similar to 
that of ischaemia-reperfusion seen in brain injury and was reversible by 
nimodipine.  The similarity of these experimental conditions with aSAH has 
prompted the question of whether spreading depolarisation is associated with 
DIND.  In a recent human study of aSAH, the evolution of ischaemic stroke 
was associated with clusters of CSD and increasingly prolonged periods of 
electrocorticographic depression, the latter being restricted to areas of 
radiologically new infarct evolution149,153.  Only patients with DIND 
demonstrated a statistically significant delayed increase in the number of 
spreading depolarisations per day.  Similarly, the presence and absence of a 
delayed cluster of CSD had high positive and negative predictive values for 
DIND.  Although these are preliminary findings, spreading depolarisation in 
this context should be the subject of further investigation. 
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Summary 
 
Although progress has been made in improving the management of aSAH 
and established DIND, morbidity and mortality associated with DIND remains 
significant.  There is a paucity of good evidence to support even the most 
established therapies.  Carefully devised studies are required to investigate 
the components of haemodynamic therapy and the continuously evolving 
endovascular technologies.  In particular, emphasis must be placed on clinical 
endpoint with the aid of multimodal monitoring where appropriate.  This has 
important implications for trial size and design since DIND is an endpoint 
occurring only in a third of patients. 
 
The significant progress in our understanding of the pathophysiology of DIND 
has been marred by difficulties in differentiating between the effects of the 
initial haemorrhage and early brain injury with those of DIND and, similarly, 
between the causes and consequences of ischaemia.  Distinguishing DIND 
from angiographic vasospasm is also paramount in improving our 
understanding of this pathological process since both are closely related 
spatially and chronologically and are likely to be caused by similar 
mechanisms.  This bears on animal-based studies that have traditionally 
focused on angiographic vasospasm.  Nevertheless, the development of new 
therapeutic interventions that currently lie at the translational level hold much 
promise for future patient prognosis.   	    
Aims of the current study 
 
There are two arms to the current study: 
 
1. A prospective, randomised and controlled trial (RCT) investigating the use 
of lumbar drainage of CSF following aSAH in reducing the prevalence and 
severity of DIND. 
2.  Assessment of the hypothesised inflammatory response following aSAH 
and the effects of lumbar CSF drainage on this inflammatory response. 
	    
Part 1: Lumbar drainage 
of cerebrospinal fluid 
following aneurysmal 
subarachnoid 
haemorrhage: A 
prospective, 
randomised and 
controlled trial (LUMAS) 
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Introduction 
 
The reported prevalence of DIND is 20-35% although in those with a higher 
blood load this may be as high as 40%154-156.  It is thought to result in cerebral 
infarcts in approximately 20% of patients157 and cause 13% of all death and 
disability following aSAH155,158.  Although the underlying pathophysiological 
process is not known159, the presence of blood or its breakdown products 
within the subarachnoid space and cisterns is clearly associated with 
DIND4,25,160.  An association between the size of the blood clot following aSAH 
and the prevalence of angiographic vasospasm and DIND is historically 
attributed to Fisher25.  This has subsequently been verified161,162 and thick 
subarachnoid clot completely filling any cistern or fissure has been shown to 
be an independent predictor of DIND4. 
 
It follows from this that attempts at clearing the subarachnoid space of blood 
may potentially reduce the prevalence and severity of DIND.  Numerous 
techniques have been described to reduce the blood load including external 
ventricular drainage, cisternal drainage, intrathecal thrombolysis, head-motion 
therapy, third ventriculostomy and incision of Lillequist’s membrane163-167.  
Studies investigating cisternal drainage have reported mixed results163,168-172.  
They are small, retrospective and often combine results with other forms of 
CSF drainage (lumbar and external ventricular drainage) and intrathecal 
thrombolysis.  Trials investigating recombinant tissue-plasminogen-activator 
following aneurysm clipping have also given mixed results although a meta-
analysis of over 600 patients has demonstrated an absolute risk reduction of 
14% for DIND, 10% for poor Glasgow Outcome Scale scores and 5% for 
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death173.  Although the overall rate of complications secondary to 
thrombolysis was considered low, cisternal drains and intrathecal 
thrombolysis are not without morbidity.  Given the trend towards endovascular 
treatment for ruptured aneurysms there is now restricted access to the 
subarachnoid cisterns in most patients who traditionally would have 
undergone a craniotomy and clipping of the ruptured aneurysm.   
 
There has been some evidence to suggest that drainage of CSF via the 
lumbar cistern may be of some benefit in reducing the prevalence of 
DIND156,174.  A lumbar drain is less invasive than other forms of CSF drainage 
and is a device that is regularly used for other clinical purposes.  A recent 
study has retrospectively analysed the effects of lumbar drainage in aSAH by 
comparing the practice of two vascular neurosurgeons during the period of 
1994 and 2003156.  One surgeon routinely placed an intra-operative lumbar 
drain during clipping or endovascular coiling of an aneurysm (unless 
contraindicated), whilst the second surgeon did not.  Data was collected on 
266 patients, although following adherence to strict exclusion criteria, the 
study included a group of 167 aSAH patients.   
 
All patients received standardised care including early definitive treatment for 
the aneurysm (surgical or endovascular coiling) and optimal medical therapy.  
Patients presenting with radiological evidence of raised intracranial pressure 
and/or hydrocephalus were treated with external ventricular drainage 
regardless of future insertion of lumbar drainage.  Patients were divided into 
two groups, those that had lumbar drainage (number of patients 81) and those 
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that did not (number of patients 86).  Outcome measures included the 
development of clinically evident vasospasm, the need for endovascular 
interventions (including angioplasty and/or intra-arterial papaverine) and the 
development of vasospasm-related infarction.  Results were in favour of 
lumbar drainage.  There was a statistically significant difference in the 
incidence of clinically symptomatic vasospasm (51% in the non-lumbar drain 
group, 17% in the lumbar drain group), need for endovascular therapy (45% in 
the non-lumbar drain group, 17% in the lumbar drain group) and vasospasm-
related infarction (27% in the non-lumbar drain group, 7% in the lumbar drain 
group).  There was also a statistically significant difference between the two 
groups in disposition at discharge, length of in-patient stay and Glasgow 
outcome scores (GOS) (better in the lumbar drain group).   
 
Although a robust retrospective study, there were certain limitations.  The 
study had a degree of selection bias with a tendency of higher Fisher grades 
(those in group 3-4 and group 4) not to have lumbar drainage.  Logistic 
regression analysis and subgroup analyses showed that following correction 
for this bias, results were still in favour of lumbar drainage.  Other limitations 
of the study include the long period in which patients presented to the 
department (9 years) and the inherent limitations to retrospectively analysing 
case notes.  In addition, comparing the practice of two neurosurgeons 
introduces another bias.  Other features which could be addressed in a future 
study include quantification of the amount of CSF drainage (including the 
amount of intraoperative drainage) and the use of lamina terminalis 
fenestration during the operation and the implications this would have in the 
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outcome measures175.  These factors have not been adequately addressed in 
this study.  A prospective, randomised and controlled trial will provide a solid 
scientific platform upon which to investigate the use of lumbar drainage 
following aSAH156,175,176. 	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Aims of the study 
 
The aim of this study is to conduct a prospective, randomised and controlled 
trial to investigate the use of lumbar drainage of CSF following aSAH. 
 
The following questions are to be answered: 
1. In aSAH patients, does lumbar drainage reduce the prevalence and severity 
of DIND?   
2. Does lumbar drainage improve long-term clinical outcome following aSAH?   
3. Does lumbar drainage affect the prevalence of chronic hydrocephalus and the 
need for CSF shunting following aSAH?   
4. Can lumbar drainage be incorporated into the treatment plan for aSAH in a 
safe and effective manner? 	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Materials and Methods 
Patients 	  
This single-centre prospective randomised controlled trial commenced 
recruitment of patients with aSAH in October 2006 and closed recruitment in 
July 2010 as per protocol (appendix 1).  Patients admitted to the neurosurgery 
department at Leeds General Infirmary with aSAH were assessed for 
suitability according to inclusion criteria (table 2).  The protocol was approved 
by the Leeds West Research Ethics Committee (October 2006). 
 
Procedure and interventions 	  
Written consent (or assent obtained from relatives in those unable to give 
informed consent) (appendices 2 and 3 respectively) was obtained and the 
patient was randomised to either the study group of insertion of a lumbar drain 
in addition to standard therapy or the control group of standard therapy alone.   
 
Standard therapy consisted of management in a neurosurgical high 
dependency unit by a multidisciplinary neurovascular team, fluid replacement 
to maintain euvolaemia and 60 mg of oral nimodipine administered every four 
hours.  CT angiography ± DSA was performed to confirm the presence of a 
cerebral aneurysm and the aim was for early aneurysm treatment.  Aneurysm 
treatment was performed using either endovascular or surgical techniques as 
assessed by the treating neurovascular surgeon and the interventional 
radiologist.  In those patients demonstrated to have multiple aneurysms,  
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Table 2-Inclusion criteria for recruiting patients.   
Age 18 years or over. 
Written informed consent or relative 
assent obtained. 
Proven aneurysmal subarachnoid 
haemorrhage. 
World Federation of Neurological 
Surgeons grade 1-3 (appendix 1.2)1. 
Fisher grade 2, 3 or 4 on initial CT 
scan (appendix 1.3). 
Recruitment prior to 96 hours post-
haemorrhage2. 
No contraindication to lumbar drain3. 
 
1.  Assessed following transfer to the recruiting centre and resuscitation (including treatment 
of acute symptomatic hydrocephalus thought to be contributing to a deteriorating Glasgow 
Coma Score (GCS) with an external ventricular drain where relevant).   
2.  If presentation was beyond four days, according to the trial hypothesis, pathways that may 
lead to DIND may already have been established. 
3.  This includes bleeding diathesis, large supratentorial intracerebral/subdural haematomas 
causing midline shift and any size of posterior fossa intracerebral haematoma.  Small 
intraventricular haemorrhage per se was not deemed a contraindication although significant 
ventricular haemorrhage was excluded. 
 60	  
attempts at treatment were applied to all aneurysms where possible although 
treatment priority rested with the aneurysm responsible for the haemorrhage.  
If a patient was diagnosed with a DIND, hyperdynamic therapy was instituted 
to improve cerebral perfusion (crystalloid and colloid fluids ± inotropes to 
augment MAP).  If deemed appropriate, further DSA and intra-arterial 
nimodipine ± TBA were performed regardless of the presence or absence of 
large vessel angiographic vasospasm. 
 
If randomised to the study arm, the patient underwent insertion of a 
MedtronicR lumbar intrathecal catheter into the lumbar cistern.  This was 
performed using an aseptic technique with local anaesthesia (or under 
general anaesthesia if at the same time as aneurysm treatment).  A 14-gauge 
Tuohy needle was inserted into the lumbar cistern and lumbar catheter was 
inserted through this needle to the length of 20 cm and secured.  The catheter 
was connected to a MedtronicR Becker drainage system adjusted hourly to 
drain 5-10 ml of CSF per hour.  This remained in-situ until the CSF was visibly 
clear or for ten days (whichever was the sooner).  Following screening and 
recruitment, patients were not subjected to further DIND prevention trials. 
 
Outcome measure 	  
The primary outcome measure was the prevalence of DIND.  This was 
defined as a drop in consciousness (one motor score or two eye/verbal scores 
of the GCS) or a new focal neurological deficit at least 96 hours post 
haemorrhage, not present immediately after aneurysm treatment and 
following exclusion of other causes.  These other causes included seizure, 
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hydrocephalus, re-bleed, hypoxia/respiratory failure, end-organ failure, sepsis 
and electrolyte disturbance.  This diagnosis could be made within 21 days of 
ictus.  TCD, CT-A and CT-P were utilised when required to aid management.  
Angiographic vasospasm was not a pre-requisite for diagnosing DIND in this 
cohort of non-comatosed aSAH patients with a good WFNS grade177. 
 
Secondary outcome measures were: MRS at day 10 and at six months 
following haemorrhage, persisting neurological deficit at discharge in those 
who have had a DIND, radiologically confirmed established infarct (as 
assessed by CT when performed as part of clinical care only) and the 
prevalence of ventriculoperitoneal CSF shunting.  
 
Randomisation 
 
Randomisation to treatment group was performed by randomly permuted 
blocks of 20 with an allocation ratio of 1:1 using an online package 
(http://www.randomization.com).  Instructions on the next intervention were 
sealed in an envelope and numbered at the start of the study.  The research 
team were blinded to any information about block size and the envelopes 
were prepared independently from the research team involved in recruiting 
patients and managing the trial.  The research team opened the envelopes 
sequentially at the time of randomisation only. 
Blinding 	  
 
Although treatment allocation could not be blinded, clinicians/investigators 
were masked to outcomes when possible.  MRS at six months was obtained 
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by the investigators (Y.A and D.B) blinded to the treatment allocation via a 
structured telephone interview directly with the patient (or their primary carer if 
the patient was unable to communicate on the phone) as previously 
described178.  Blinding of treatment allocation was not always possible for 
MRS obtained at ten days post haemorrhage but was performed by a 
physiotherapist involved with the patient’s clinical care and verified by the 
investigators (Y.A and D.B).  All diagnoses of DIND were made by a 
multidisciplinary neurovascular team (neurosurgeons, neurointensive care 
anaesthetists and neuroradiologists) and were prospectively and 
retrospectively verified (from prospectively collected clinical parameters 
(appendices 4 and 5) and electronically recorded blood results/picture 
archiving and communication system) by the investigators blinded to the 
treatment allocation.  With the exception of a few additional clinicians, the 
multidisciplinary team had remained largely unchanged over the four-year 
study period.  No disagreements occurred between prospective and 
retrospective assessments due to the relative ease of assessing the 
neurology of good grade patients, the absolute diagnostic criteria for DIND 
and the objective investigations required to exclude other causes of 
neurological deterioration.  Neuroradiologists blinded to the treatment 
allocation reported radiologically confirmed infarcts as part of routine clinical 
care.  
 
Statistical Analysis 	  
The power calculation was based on a prevalence of DIND of 40% as 
previously audited in the neurosurgical department at Leeds General Infirmary 
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and an estimated benefit of a 20% absolute reduction in DIND with lumbar 
drainage (based on the current evidence for lumbar drains156).  For 85% 
power this required 105 patients in each arm.  Planned interim analyses were 
performed following recruitment of 40 patients (to establish adverse effects 
only) and 100 patients.  The data monitoring committee/statistical consultation 
advocated continuation of the trial to completion following these analyses. 
 
Baseline data on all patients with aSAH was collected prospectively on 
confirmation of the aneurysmal cause of the haemorrhage.  The primary 
analysis was performed on an intention-to-treat basis.  A secondary analysis 
with some patients being excluded was also performed (see below).  The 
analysis of the primary outcome was a categorical frequency comparison with 
the Chi-squared (χ2) test.  Comparison of secondary outcome data between 
groups was performed with several tests.  All numerical data were assessed 
for normality using the Shapiro-Wilks test and Q-Q plots.  Normal numerical 
data was tested with the independent t-test and data not normally distributed 
with the Mann-Whitney U test.  Categorical frequencies were compared with 
the χ2 test or Fisher’s exact test when a cell size was less than 5.  p<0.05 was 
considered statistically significant.  All statistical tests were conducted with 
IBM Statistics for the Social Sciences (SPSS) version 18.  This study was 
registered with ClinicalTrials.gov (NCT00842049). 	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Results 
 
The trial profile is shown in figure 1.  From a total of 426 patients with aSAH, 
210 were recruited and randomised to the trial.  The main reasons for 
exclusions were poor WFNS grade and delayed presentation following ictus.  
The primary analysis followed intention-to-treat principles and included all 210 
patients.  A secondary analysis was performed that excluded those patients in 
the study group that could not receive lumbar drain/CSF drainage therapy due 
to an inability to place a functioning drain and those patients in the control and 
study groups that were treated for hydrocephalus with early external 
ventricular drainage (within 14 days of ictus).  Two randomised patients that 
were initially diagnosed with aSAH based on CT-A were subsequently found 
not to be aneurysmal on formal angiogram and were therefore excluded as 
part of this secondary analysis. 
 
Table 3 shows baseline patient characteristics including age, gender, WFNS 
grade, Fisher grade, aneurysm type and treatment modality in the two groups.  
There is a greater prevalence of multiple aneurysms in the study group and 
hydrocephalus requiring external ventricular drainage in the control group.  
 
Table 4 shows the primary intention-to-treat analysis of primary and 
secondary outcome measures.  There was a significantly lower prevalence of 
DIND in the study group (prevalence of DIND in the control group 35% 
(confidence interval (CI) 26.2-45.2%) versus 21% (CI 13.6-30.0%) in the study 
group (p=0.021)).  A better outcome at ten days post ictus was noted for 
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those in the study group.  There were no significant differences noted in the 
other outcome measures including MRS at six months.   
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Figure 1- Trial profile. 1. Between 2006 and 2008 endovascular services at Leeds General 
Infirmary were occasionally unavailable and so following initial assessment and stabilisation; 
some patients were transferred to other neurosurgical units for their continued management. 
2.  Initially good World Federation of Neurological Surgeons (WFNS) grade with very early 
subsequent neurological and/or systemic deterioration prior to recruitment to the trial. 
3.  Radiologically or due to heparin therapy given during endovascular treatment, which 
continued beyond the four-day post ictus window allowable for recruitment. 
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Table 3 (overleaf)-Baseline characteristics for patients in both arms of the trial 
Abbreviations: M-male, F-female, WFNS-World Federation of Neurological Surgeons, ICA-
internal cerebral artery, OA-opthalmic artery, PComA-posterior communicating artery, MCA-
middle cerebral artery, ACA-anterior cerebral artery, PA-pericallosal artery, AComA-anterior 
communicating artery, VA-vertebral artery, BA-basilar artery, SCA-superior cerebellar artery, 
PICA-posterior inferior cerebellar artery, PCA-posterior cerebral artery. 
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Characteristic Control 
Group 
Study 
Group 
Significance 
Cohort size 105 105 N/A 
Median age (interquartile range)/years 56.1 (45.0-
63.6) 
53.3 
(44.9-
62.2) 
p=0.38 
Sex (M:F) 1:3.6 1:4 p=0.74 
WFNS grade 
(% of group) 
1 63.8 68.6 p=0.47 
2 31.4 25.7 
3 4.8 5.7 
Fisher grade 
(% of group) 
2 43.8 37.1 p=0.33 
3 41.9 39.1 
4 12.4 10.5 
3+4 1.9 13.3 
Aneurysm 
type (number 
of patients)1 
 
 
 
Anterior 
circulation 
 
ICA 6 8 p=0.25 
OA 1 2 
PComA 21 16 
MCA 17 21 
ACA 18 8 
PA 2 5 
AComA 26 25 
Posterior 
circulation 
VA 0 1 
BA 3 10 
SCA 1 1 
PICA 6 4 
PCA 3 3 
None 1 1  
Multiple aneurysms/% of group 18.1 32.6 p=0.017 
Aneurysm 
Treatment 
Coiling 86 78 p=0.45 
Clipping 13 16 
Both2 4 10  
None3 2 1  
Procedural 
adverse 
events4 
Aneurysm rupture/coiling 
Aneurysm rupture/clipping  
Ischaemia post procedure5 
3 
2 
9 
3 
4 
11 
N/A 
Hydrocephalus requiring early external 
ventricular drainage 
15 5 p=0.032 
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Table 4-Primary intention-to-treat analysis 
Abbreviations: DIND-delayed ischaemic neurological deficit, MRS-Modified Rankin Score, 
CSF-cerebrospinal fluid. 
Outcome measure Control 
Group 
(n=105) 
Study 
Group 
(n=105) 
Significance 
Number of patients with DIND (% of 
group) 
37 (35.2%) 22 (21.0%) p=0.021 
 
Relative risk of DIND for control versus 
study (95% confidence interval) 
1.7 (1.1-2.6) 
Number of patients diagnosed with a 
DIND and a persisting neurological 
deficit at discharge (% of group) 
13 (12.4%) 10 (9.5%) p=0.51 
Type of DIND (% 
of patients with 
DIND) 
Focal 21 (56.8) 9 (40.9) p=0.29 
Altered 
consciousness 
9 (24.3) 8 (36.4) 
Both 7 (18.9) 5 (22.7) 
Number of patients with radiologically 
confirmed infarct/number of patients 
imaged (% of total group) 
22/66 
(21%) 
15/60 
(14.3%) 
p=0.21 
Number of patients with MRS of 0-2 at 
day ten (% of group) 
39 (37.5%) 58 (55.2%) p=0.009 
Number of patients with MRS of 0-2 at six 
months (% of group) 
83 (81.4%) 81 (80.2%) p=0.83 
Number patients dead at six months (% 
of group) 
5 (4.8%) 4 (3.8%) P=1.00 
Number of patients requiring permanent 
CSF shunting (% of group) 
8 (7.6%) 6 (5.7%) p=0.58 
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Table 5-Secondary analysis with exclusions 
Abbreviations: DIND-delayed ischaemic neurological deficit, MRS-Modified Rankin Score, 
CSF-cerebrospinal fluid 
Outcome measure Control 
Group 
(n=89) 
Study 
Group 
(n=87) 
Significance 
Number of patients with DIND (% of 
group) 
32 (36.0%) 14 
(16.1%) 
p=0.003 
Relative risk of DIND for control versus 
study (95% confidence interval) 
2.2 (1.3-3.9) 
Number of patients diagnosed with a 
DIND and a persisting neurological deficit 
at discharge (% of group) 
10 (12.2%) 7 (8.0%) p=0.47 
Type of DIND Focal 20  4 p=0.034 
Altered 
consciousness 
6 4 
Both 6 6 
Number of patients with radiologically 
confirmed infarct/number of patients 
imaged (% of group) 
18/51 
(20.2%) 
10/46 
(11.5%) 
p=0.11 
Number of patients with MRS of 0-2 at 
day ten (% of group) 
38 (42.7%) 52 
(59.8%) 
p=0.02 
Number of patients with MRS of 0-2 at six 
months (% of group) 
71 (82.6%) 72 
(86.7%) 
p=0.45 
Number of patients dead at six months 
(% of group) 
3 (3.4%) 3 (3.3%) p=1.00 
Number of patients requiring permanent 
CSF shunting (% of group) 
3 (3.4%) 3 (3.4%) p=0.98 
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Two patients with a lumbar drain developed meningitis and one patient 
developed a lumbar drain exit site infection.  All cases were treated with 
antibiotics with no permanent morbidity.  There were thirteen cases of 
organism growth in CSF or the lumbar drain tip that had no clinical 
significance.  Lumbar drains could not be inserted/did not function on insertion 
in 9 patients.  Concerns about a post-operative intracranial haematoma 
resulted in cessation of lumbar drainage in 3 patients.  There was one case of 
symptomatic hydrocephalus requiring external ventricular drainage despite a 
patent and functioning lumbar drain in-situ.  There was one case of continued 
low-pressure headaches several weeks after removal of the lumbar drain.  
This required a dural blood patch.  There were no cases of neurological 
deterioration/re-bleed of aneurysm secondary to lumbar drain insertion.   
 
Mean CSF drainage was 138 ml/24 hours (confidence interval 124-152 ml/24 
hours) (data missing in 16 patients).  The mean duration of drainage was 5.0 
days (CI 4.5-5.6 days, range 1-12 days).  Drain insertion occurred on day 1 
post ictus in 31%, day 2 in 32%, day 3 in 26% and day 4 in 11% of patients.  
Drain insertion occurred prior to aneurysm treatment in 31%, on the day of 
aneurysm treatment in 40% (approximately half immediately prior to treatment 
and half several hours after treatment) and after aneurysm treatment in 29% 
of patients.  For the first 53 patients in the lumbar drain group, the opening 
pressure was recorded.  Mean opening pressure (95% confidence intervals) 
was 27.3 cmH2O (24.9-29.7 cmH2O). 
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Table 6 shows the prevalence of DIND in the control and study groups 
stratified by Fisher grade.  There was a trend for a lower prevalence of DIND 
in Fisher grades 2, 3 and 4 although this was statistically significant in Fisher 
3 patients only.  Table 7 shows the prevalence of DIND in the study group 
stratified by the day of drain insertion relative to the haemorrhagic ictus.  The 
relative risk of DIND for control versus study group was greater in those with 
drain insertion on days 3 and 4 post ictus.  Approximately 94% of all patients 
had presented to the neurosurgery department within 48 hours of ictus.  
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Table 6-Prevalence of DIND stratified by Fisher grade 
Abbreviations: DIND-delayed ischaemic neurological deficit 
Fisher 
Grade 
Control Group: 
Number of patients 
with DIND/Total 
number in subset 
(% of subset) 
Study Group: 
Number of 
patients with 
DIND/Total 
number in 
subset (% of 
subset) 
Significance Relative Risk of 
DIND for control 
versus study (95% 
confidence 
intervals) 
2 8/46 (17.3) 3/39 (7.7) p=0.21 2.53 (0.62-10.3) 
3 22/44 (50) 9/41 (22.0) p=0.013 3.56 (1.38-9.16) 
4 6/13 (46.2) 3/11 (27.3) p=0.42 2.29 (0.41-12.7) 
3+4 1/2 (50) 7/14 (50) p=1.00 0.50 (0.036-6.86) 
 	  
Table 7-Prevalence of DIND in the study group stratified by day of lumbar drain 
insertion following ictus 
Abbreviations: DIND-delayed ischaemic neurological deficit 
Day of 
insertion 
post 
ictus 
Number of patients 
in each sub-group 
Prevalence of DIND 
(% of sub-group)  
Relative Risk of DIND for 
control versus study (95% 
confidence intervals) 
1 34 26.7 1.5 (0.9-2.6) 
2 31 20.0 
3 28 15.4 2.2 (1.0-4.7) 
4 12 18.2 
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Discussion 
Summary of findings 	  
This study has demonstrated that the use of lumbar drainage of CSF following 
aSAH significantly reduces the prevalence of DIND and improves early clinical 
outcome.  There is no significant difference noted in the clinical outcome at six 
months or in the need for permanent CSF shunting although there was a non-
significant decrease in radiologically confirmed infarct.  The incidence of CSF 
infection in those with lumbar drains is less than 2%, with no permanent 
morbidity associated with their use.  A secondary analysis designed to 
exclude patients that may have introduced bias into the intention-to-treat 
model mirrored the primary analysis in findings.  Patients with DIND in the 
study group tended to have a higher rate of altered consciousness (either with 
or without a focal deficit) than the equivalent patient in the control group. 
 
CSF blood clearance 	  
Lumbar drains have been described as a less invasive form of CSF 
drainage156,174,179.  In a retrospective comparison of two patient cohorts with 
and without lumbar drains following aSAH, the difference in the prevalence of 
DIND was noted to be 51% in those patients without lumbar drains and 17% 
with lumbar drains156.  This difference is larger than that demonstrated in the 
current study (35% vs 21%) and may be explained by the retrospective study 
methodology and a selection bias between the two cohorts in the non-
randomised study.  Their prevalence of DIND of 51% is higher than that 
reported in the literature.  The reported prevalence is significantly influenced 
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by diagnostic criteria and is generally reported to be 20-35% with a slightly 
higher prevalence in those with high blood loads154-156.   
 
The hypothesis that lumbar drains confer benefit by reducing blood load has 
support from the current study.  The trial protocol consisted of volume-driven 
CSF drainage with the aim of 5-10 ml CSF per hour until the CSF was visibly 
clear.  This objective was achieved in most patients.  Supporting this 
hypothesis is the finding that lumbar drains conferred the most benefit to 
patients with Fisher 3 grade aSAH.  On the other hand however, there was no 
additional benefit to placing drains very early (i.e. within 48 hours of 
haemorrhage).  This is not explained by the late presentation of patients to the 
neurosurgical centre since 94% of all patients in the study had presented 
within 48 hours of ictus (i.e. there is no selection bias of late lumbar drain 
insertion being associated with late patient presentation to the hospital which 
may have been a result of milder symptoms and thus a milder haemorrhage).  
This subgroup analysis must be interpreted with caution due to the small 
number of patients involved. 
Intracranial pressure control 	  
An alternative hypothesis regarding the mechanism of benefit conferred by 
lumbar drainage is intracranial pressure (ICP) control.  In the current study, 
opening lumbar cistern pressure was invariably raised in all of the patients 
administered with lumbar drains (when tested) and drainage resulted in 
immediate improvements in the severity of headaches in most patients.  
Although drainage of CSF was volume driven, intracranial pressure was likely 
to have been lowered by the volumes of CSF drained via the lumbar cistern.  
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This is supported by the observation that most patients with a lumbar drain in 
situ for more than 72 hours exhibited clinical symptoms of low intracranial 
pressure very distinct from the initial presenting features of the aSAH.  These 
symptoms improved following removal of the drain.  Previous studies have 
demonstrated elevated ICP (as measured in the ventricle) several days after 
aSAH regardless of the volume of blood load180-182.  Although associated with 
poor clinical grade, elevated ICP has been seen in 50-90% of patients with 
good clinical grade180,181,183 and is associated with a poor clinical 
outcome180,184.  Severe angiographic vasospasm has been shown to be more 
common with high ICP although association with DIND is weak185.  A 
previously reported comparison of simultaneous lumbar and ventricular 
pressure in this setting demonstrated that both pressure readings reflect each 
other closely186.  Drainage of 5-20 ml of CSF via a lumbar drain has been 
shown to approximately halve ICP in aSAH and brain injury patients187.  
Additional benefits observed included an improvement in regional CBF and 
PtiO2.  Hydrocephalus requiring treatment with external ventricular drainage 
was more frequently seen in the control group rather than the study group.  
Some patients with lumbar drainage may have had this clinical effect masked 
by the presence of a lumbar drain.  This adds further support to the 
hypothesis that patients with a lumbar drain in the current study would have 
been likely to benefit from a reduction in ICP.  It is plausible that this may 
have improved ischaemic thresholds by improving oxygenation and CBF and 
thus reducing the prevalence of DIND.  
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Complications 	  
Since the current study cohort consisted of good WFNS grade patients with 
aSAH (grades 1-3), the benefits of lumbar drainage have been demonstrated 
in this population only.  Although results cannot be extrapolated outside of the 
study cohort, there is no reason to suggest that aSAH patients of poor grade 
(grades 4-5) would not benefit from lumbar drainage.  Patients of poor grade 
are more likely to have higher blood loads and a higher ICP.  They are 
however also more likely to have an intracerebral and extensive 
intraventricular haemorrhage, which raises the issue of safety.  Neurological 
deterioration that has been reported following lumbar drain insertion156,188 is 
more difficult to assess in this cohort of ventilated and comatose patients.  
Although re-bleed of the ruptured aneurysm has been reported following 
insertion of an external ventricular drain or lumbar puncture/drain insertion, 
this risk has not been proven179,189,190.  This problem was not encountered in 
the current study despite the fact that approximately half the patients 
underwent insertion of a lumbar drain with an unprotected aneurysm.  One 
patient reported continued low-pressure headaches requiring a blood patch.  
This is consistent with the reported incidence of this complication with lumbar 
drain use following trans-sphenoidal surgery (1.3%)191.  Meningitis secondary 
to lumbar drainage has been shown to be less than 2% in the current study, 
which is half that previously described192.  No permanent morbidity was 
associated with infection.   
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Permanent CSF diversion 	  
Although lumbar drainage has previously been shown to reduce the need for 
permanent CSF diversion (24% with lumbar drain vs 36% without lumbar 
drain)156, this reduction has not been consistently demonstrated174.  In the 
current study, there was no difference in the need for permanent CSF 
diversion between the two groups.  In contrast, cisternal CSF drainage and 
irrigation has been associated with a higher rate of permanent CSF diversion, 
with the volume of drainage proportional to this rate168,172,193.  It is unclear why 
lumbar drainage did not increase the occurrence of long-term hydrocephalus.  
A possible explanation is that the patient’s natural CSF channels are 
encouraged rather than bypassed (which may occur with cisternal and 
external ventricular drains) so allowing normal pathways to re-establish 
following blood clearance.  Acute and chronic hydrocephalus is thought to 
result from tentorial/ventricular obstruction and blockage of arachnoid 
granulations with blood respectively194,195.  Either mechanism is likely to be 
resisted and minimised by the negative downward pressure drawing CSF into 
the lumbar cistern, an advantage of lumbar drainage over supratentorial CSF 
drainage.   
Clinical outcome 	  
Although patients in the study group demonstrated improved clinical outcome 
ten days following ictus, this improvement was not maintained at six months 
(there was a trend for patients with lumbar drains to have improved six-month 
outcome but this was only seen in the secondary analysis and was not 
statistically significant).  It is well recognised that clinical trials powered to 
detect changes in DIND occurrence often report difficulties in detecting 
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patient-centred ‘down-stream’ clinical outcome196.  The effect size of a 
treatment on DIND does not translate into the same effect size on the clinical 
outcome.  In addition, the MRS has been noted to lack specificity in detecting 
subtle yet meaningful changes in cognition and functioning.   
Limitations of the trial 	  
There are subtle differences in the baseline cohort characteristics between 
the two groups of the trial.  There is no explanation as to why there are more 
patients with multiple aneurysms in the study group.  More patients in the 
control arm had required external ventricular drainage for hydrocephalus.  
This is likely to be due to the masking of hydrocephalus in those with a lumbar 
drain and so obviating the need for additional supratentorial.  Limitations of 
the study include a reliance on DIND as the primary endpoint, which can be a 
subjective endpoint177.  This subjectivity has been minimised by using a 
homogenous cohort of good WFNS grade aSAH patients with very strict 
diagnostic criteria for DIND, objective investigations to exclude other causes 
of neurological deterioration and multiple verification of the diagnosis of DIND.  
A second limitation to the study is the reliance on imaging performed as part 
of routine clinical care only; although there was a trend for fewer radiologically 
confirmed infarcts in the lumbar drain group, this is based on the incorrect 
assumption that those without clinical need for imaging will not have infarcts.  
A third limitation to this study is the difficulties associated with blinding 
treatment allocation and obtaining unbiased outcome measures.  Being a 
single-centre trial has the advantage that only few clinicians were involved 
during the study period and so quality and consistency of diagnoses and 
treatment should be high.  The disadvantage is the small size of the trial not 
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powered to detect changes in clinical outcome and the lack of information 
regarding reproducibility in other neurosurgical centres, particularly those in 
other countries where management of patients is likely to be markedly 
different. 
 
	    
Part 2: The role of 
cytokines in 
aneurysmal 
subarachnoid 
haemorrhage and 
delayed ischaemic 
neurological deficit 	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Introduction 
The physiology and immunology of inflammation 	  
The immune system is designed to defend against foreign antigens.  It 
constitutes both cellular components such as B and T lymphocytes, 
monocytes, macrophages and neutrophils; and molecular components such 
as complement, acute-phase proteins and cytokines197.  When the immune 
system is activated, a delicate balance between pro-inflammatory and anti-
inflammatory states is maintained by the innate and adaptive immune 
systems198.  T-cell lymphocytes, B-cell lymphocytes and natural killer (NK) 
cells all constitute part of the adaptive immune system.  T-cell lymphocytes 
include helper CD4+ T-cells and cytotoxic CD8+ T-cells.  Following antigen 
activation, the former can differentiate into Th1 (associated with pro-
inflammatory cytokines and cell mediated immunity), Th2 (associated with 
anti-inflammatory cytokines and humoral immunity) and regulatory T-cells198.   
 
An immune response involves both cellular and humoral components and can 
be subdivided into four distinct stages: 1. recognition and activation, 2. 
proliferation, 3. effector and 4. memory199.  The first stage relies on 
presentation of peptide antigens on the surface of antigen-presenting cells 
(such as microglia, dendritic cells and monocytes/macrophages) to T-cells197.  
Cytokines are also actively involved, both for activation and suppression of 
this process.  The second proliferation phase ensures that activated 
lymphocytes can produce expanded populations of T- and B-lymphocytes.  
Effector killer T-cells and B-cells can induce apoptosis and antibodies 
respectively, resulting in elimination of foreign antigens.  The final phase of 
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memory constitutes the persistence of a small number of these immune cells 
that can respond quickly following further exposure to the same antigens197. 
CNS inflammation 	  
Our understanding of inflammation in the CNS is largely based on animal 
studies and the demonstration of various inflammatory mediators and cells in 
plasma, serum, CSF and pathological brain tissue200.  These compartments 
may not reflect the injured brain itself.  Intracerebral microdialysis catheters 
have been developed with increasingly larger membrane cut-offs that provide 
some insight into the extracellular fluid (ECF).  Inflammation is a cardinal host 
defence response to injury, tissue ischaemia, autoimmune responses or 
infection201.  This process often involves recruitment and invasion of immune 
cells and activation of mediators such as kinins, cyclooxygenase products and 
cytokines.  Inflammation may manifest as a local response or a more 
generalised systemic ‘acute phase’ response.  Historically, the brain has been 
considered to be an immune privileged organ.  Early pioneering work had 
demonstrated that allogeneic tissue grafts were not rejected when implanted 
into the brains of experimental animals202.  This was subsequently thought to 
be due to the lack of connection between the lymphatic system and the CNS.  
The CNS was thought not to have native antigen-presenting cells197. 
 
More recently, it has been demonstrated that rejection does occur following 
graft implantation into the CNS, there is a connection between CSF 
compartments and cervical lymphatics and resident antigen-presenting cells 
do exist197.  In healthy CNS tissue, inflammatory mediators are expressed at 
very low levels and cytokine receptors are expressed constitutively in the 
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CNS201.  In response to tissue injury or infection, early and rapid glial 
activation and release of inflammatory mediators is followed by slower 
leukocyte recruitment201.  In a disease state, the presence of damaged cells 
and debris causes resting microglia to transform into migrating macrophages.  
These in turn can produce cytokines and trophic factors that can affect 
neighbouring cells and recruit peripheral inflammatory cells. 
 
Cytokines are well recognised as low molecular weight pleiotropic 
glycoproteins that act autocrinally and paracrinally on target cells to promote 
and control inflammatory processes203.  Much of our understanding of 
cytokines is derived from studies of their immunoregulatory properties that 
depict cytokines as operating within tightly regulated complex networks where 
individual elements operate to potentiate and/or modulate each other’s 
effects.  Furthermore, functional redundancy within these networks can 
enable different cytokines to induce similar responses through their use of a 
common receptor.  Among their numerous roles, cytokines regulate the 
expression of cell adhesion molecules in microvascular endothelial cells. Cell 
adhesion molecules consist of three families responsible for interactions 
between leukocytes and endothelial cells: endothelial cells express the 
immunoglobulin supergene family members, intercellular adhesion molecules 
(ICAMs) (including ICAM-1) and P- and E-selectin, while leukocytes express 
L-selectin and integrins204.   
 
In addition to the inflammatory components produced within the CNS, the 
BBB may also be compromised in disease states and thus allow transport 
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(active or passive) of inflammatory mediators into the CNS201.  Inflammatory 
mediators may be themselves involved in the breakdown of the BBB in certain 
pathologies205.  In ischaemic brain damage, a local inflammatory response in 
addition to peripheral inflammatory processes and immune alterations occur 
with interleukin (IL)-6 considered a key mediator in this acute phase systemic 
response206.  To support this, peripheral white cell count has been shown to 
be elevated soon after ischaemic stroke and leukocyte infiltration has been 
detected within the ischaemic lesions and the CSF of patients with ischaemic 
stroke207-209.  In the acute phase of ischaemia, cell death in the core is likely to 
be secondary to necrosis, whereas following reperfusion, penumbral neurons 
may undergo apoptosis210.  An increasing body of evidence implicates CNS 
inflammation in this process210. 
 
What follows is a brief overview of the key inflammatory mediators under 
investigation in the current study.  The evidence for their involvement in 
traumatic brain injury (TBI) and ischaemic stroke will be included.  Only 
experimental evidence for their involvement in SAH will be discussed at this 
stage (for clinical studies in aSAH, see next section).  	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Pro-inflammatory Mediators 	  
Interleukins-1α and β (IL-1α and 1β) 
The IL-1 family is a group of cytokines considered key mediators of neural 
injury in the CNS following ischaemic stroke and TBI211.  IL-1α and β are 
constitutively expressed in the brain at low concentrations but their expression 
can be stimulated by bacterial and viral products, other cytokines (such as 
tumour necrosis factor (TNF)-α), cellular injury and hypoxia.  They are 
involved in the host defence against disease and many of their actions are in 
the CNS resulting in systemic effects (including fever and the acute-phase 
response).  They are considered to be largely pro-inflammatory, whilst their 
effects are antagonised by the endogenous IL-1 receptor antagonist (IL-
1ra)200.   
 
Although the mechanism by which IL-1 exerts CNS injury is unknown, there is 
some experimental data to suggest that increases in body temperature may 
exacerbate neuronal injury and is associated with a poor clinical outcome in 
stroke or head injury211,212.  Experimental data would suggest that IL-1 has 
positive effects to reduce cell death (such as inhibition of glutamate release, 
inhibition of calcium influx and inhibition of γ-aminobutyric acid (GABA) 
transmission)213.  This inhibition of excitatory and inhibitory pathways may 
result in excitation, inhibition and cell death.  Calcium influx may also be 
stimulated via N-methyl-D-aspartate (NMDA)-receptor ion channels.  Effects 
on glial cells including astrocytes are also variable.  The effect of IL-1 on 
cultured astrocytes can change the expression of numerous genes encoding 
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chemokines, growth factors, adhesion molecules, matrix metallopeptidase 
(MMPs) and cytokines (including IL-6) which may contribute to neurotoxicity 
and paradoxically also promote neuronal survival211.  IL-1 has numerous 
effects on the endothelium that result in expression of molecules involved in 
leukocyte recruitment and adhesion (including ICAM-1).  This has implications 
for the integrity of the BBB.  The overall effect depends on the temporal 
expression profile of these molecules.  This makes the interpretation of these 
findings difficult in the context of IL-1-mediated effects in-vivo.  Figure 2 is a 
summary of the proposed cellular actions of IL-1β in neuronal injury. 
 
In experimental SAH models, IL-1β was activated early after SAH and a 
selective caspase-1 inhibitor inhibited its activation and attenuated the 
mortality, neurological impairment, BBB disruption and brain oedema214.  S-
100B protein concentration in the serum (a marker of BBB permeability) was 
elevated following experimental SAH215.  This effect was attenuated by the 
neutralization of IL-1β activity.  This protective effect was also associated with 
reduced MMP-9 induction. This is a proteolytic enzyme that has been 
implicated in the breakdown of the BBB in ischaemia and in haemorrhagic 
transformations in ischaemic stroke216,217.  
 
Similarly, simvastatin treatment resulted in reduced IL-1β expression and 
ischaemic injury in a rat model of middle cerebral artery occlusion218.  The 
transcription factor nuclear factor-kB (NF-kB) (responsible for expression of 
proinflammatory genes) was upregulated in both transient and permanent  
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artery occlusion.  Its activation was attenuated during ischaemia with 
simvastatin treatment.   
Interleukin-6 (IL-6) 	  
IL-6 is produced by mononuclear phagocytes, T cells and endothelial cells197.  
IL-6 stimulates the growth of mature B cells and promotes the synthesis of 
acute phase proteins by the liver including C-reactive protein and fibrogen219.  
IL-6 can stimulate expression of MMPs including MMP-9.  It is also involved in 
liberating adhesins in the process of leucocyte aggregation and adhesion to 
the vascular wall.  It is itself synthesised as an acute phase reactant.  
Although considered pro-inflammatory, IL-6 has been shown to exhibit some 
anti-inflammatory effects that are supported by its ability to inhibit TNF-α 
synthesis, induce the nerve growth factor and IL-1ra, promote neuronal 
differentiation and survival and counteract NMDA-mediated toxicity220.  Its 
constitutive expression in the healthy brain would support its regulatory role 
during normal physiology. 
 
Plasma IL-6 was induced following experimental stroke in mice, peaking at 
four hours206.  In a clinical study, plasma IL-6 levels correlated with blood 
volume, mass effect and GCS following intracerebral haemorrhage221.  In 
patients with ischaemic stroke, early plasma IL-6 levels were higher than in 
healthy controls and correlated with stroke volume and poorer outcome222-224.  
This is supported by similar findings in the CSF225.  In a nested case-control 
study, very high levels of plasma IL-6 were found to be a significant predictor 
of recurrent ischaemic stroke226.  It is increased following TBI in 
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Figure 2-Summary of proposed cellular actions of interleukin-1β  in neuronal injury.  All 
cell types can express and release IL-1β physiologically and following neuronal injury.  IL-1 
receptor (IL-1R1) is expressed at the surface of these cells, enabling them to respond to IL-1β 
in an autocrine and paracrine fashion.  After receptor binding, cells can produce a wide range 
of pro-inflammatory and immunoregulatory mediators that are implicated in neuronal-cell 
death or survival depending on the relative contribution of synergistic/antagonistic cytokines.  
BDNF: brain-derived neurotrophic factor; CCL2: CC-chemokine ligand 2; CXCL8: CXC-
chemokine ligand 8; E-selectin: endothelial-cell selectin; ICAM1: intercellular adhesion 
molecule 1; IL-1RA: IL-1-receptor antagonist; IL-1RAcP: IL-1-receptor accessory protein; 
MMP: matrix metallopeptidase; NGF: nerve growth factor; NO: nitric oxide; PGE2: 
prostaglandin E2; P-selectin: platelet selectin; TGF: transforming growth factor; TNF: tumour-
necrosis factor.  Source: Allan et al 2005, Nature Reviews: Immunology211. 
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plasma, CSF, cerebral ECF and brain tissue proper200,227-229.  In paediatric 
TBI patients, both plasma and CSF IL-6 levels were shown to correlate with 
the severity of the injury and outcome227.  Contrary to this, following adult TBI, 
higher ECF IL-6 seemed to exhibit a protective role and correlated with good 
outcome and survival230.  This supports a possible dual role for IL-6 in this 
setting. 
Interleukin-8 (IL-8) 	  
IL-8 is a chemokine and thus belongs to a family of cytokines that share the 
ability to stimulate leukocyte motility and directed movement.  It is produced 
by mononuclear phagocytes, T cells, platelets, endothelial cells and 
fibroblasts197.  As with IL-6, it has an important role in mediating the acute 
phase response and in stimulating adhesion molecules.  Activated neutrophils 
may contribute to brain injury by causing microvascular occlusion and the 
production of further cytokines, reactive oxygen and nitrogen metabolites and 
lipid mediators231.  Anti-neutrophil antibodies and neutrophil depletion have 
been shown to reduce neutrophil infiltration and infarct size in the ischaemic 
rat brain232,233.  IL-8 is considered an important chemokine in post-ischaemic 
leukocyte accumulation and activation234.  In an experimental ischaemia 
model, an IL-8 receptor antagonist reduced neutrophil infiltration but had no 
effect on tissue damage during permanent ischaemia234.  During transient 
ischaemia however, tissue damage was reduced and neurological function 
was improved234,235.  This suggests that these benefits are conferred during 
reperfusion.  IL-8 levels were not changed, indicating blockade of downstream 
factors. 
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Increased CSF concentration of IL-8 has been reported in humans following 
TBI and correlates with a fatal outcome228.  In patients with ischaemic stroke, 
intracellular leukocyte IL-8 concentrations, plasma IL-8 levels and IL-8 mRNA 
expressing blood mononuclear cells were noted to be higher than in 
controls236-238.  Data from a rabbit basilar SAH model suggests that IL-8 
expression within cerebral vessels may also be associated with angiographic 
vasospasm239. 
Interleukin-15 	  
IL-15 is a pleiotropic cytokine which is constitutively expressed by a large 
variety of cell types and tissues including monocytes/macrophages, dendritic 
cells, keratinocytes and epidermal skin cells240.  It enhances the phagocytic 
activity of monocytes and macrophages and induces the production of pro-
inflammatory factors such as IL-8 and monocyte chemoattractant protein-1 
(MCP-1)240.  It is implicated in various inflammatory conditions such as coeliac 
disease, inflammatory bowel disease, systemic sclerosis and rheumatoid 
arthritis.  The pathogenic role of IL-15 in multiple sclerosis has been 
extensively investigated.  IL-15 mRNA is up-regulated in blood mononuclear 
cells from patients in the secondary progressive phase of the disease and in 
active plaques241,242.  Serum and CSF levels of the mediator have been 
shown to be elevated in patients with multiple sclerosis, with a suggestion that 
systemic production was the source of CSF IL-15243.  There is limited 
evidence for its involvement in cerebral ischaemia.  In the ischaemia/hypoxia 
model of the immature rat brain, IL-15 was initially produced by blood cells 
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penetrating the injured brain but was later also synthesised by reactive 
astrocytes forming dense astrogliosis around necrotic centres244. 
Interleukin-17 	  
IL-17 is a homodimer activated by CD4+ and CD8+ activated memory T 
cells245.  It plays an important role in the maturation of haematopoietic 
progenitor cells and induces production of proinflammatory mediators.  It can 
induce stromal cells such as fibroblasts, endothelial cells and epithelia, to 
produce IL-6, IL-8, granulocyte colony-stimulating factor and ICAM-1246.  In 
both in-vitro and in-vivo models, IL-17 has also been implicated in the 
disruption of BBB tight junctions247.   
 
Its putative role in ischaemia is unclear.  Following neuronal injury, activated 
microglia accumulate and secrete pro-inflammatory cytokines such as IL-23 
via Toll-like receptors (TLRs)248.  TLRs are a family of transmembrane 
receptors able to recognise pathogen-associated molecular patterns and are 
essential in the microglial innate immune response.  This is evidence 
suggesting that a TLR2, IL-23 and IL-17 axis does exist which leads to 
neuronal apoptosis248.  This pathway is activated in animal models of 
ischaemia/reperfusion, with IL-23 functioning in the immediate stage of 
ischaemia/reperfusion injury and IL-17 (being a downstream factor) more 
important in the delayed phase248,249.  Both exogenous IL-17 addition and 
microglia release of IL-17 lead to apoptosis in an in-vitro oxygen-glucose-
deprivation reperfusion system248.  Both animal and human studies suggest 
that IL-17 expression is elevated in the ischaemic brain.  Neuronal injury 
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during oxygen-glucose deprivation may be mediated by IL-17 via the IL-17 
receptor250,251.   
Interleukin-18 	  
IL-18 is a pro-inflammatory cytokine, formerly known as interferon-γ inducing 
factor and is a member of the IL-1 family.  IL-18 and IL-1 act through related 
receptor complexes to trigger common signalling pathways252.  This cytokine 
is produced constitutively in many different cell types including macrophages, 
endothelial cells, vascular smooth muscle cells, dendritic cells and Kupffer 
cells.  Increased expression of IL-18 mRNA and protein has been reported 
during Wallerian degeneration of the rat nervous system following a nerve 
crush injury253.  The role of IL-18 following brain injury and ischaemia is 
unclear, although it could contribute to exacerbating hypoxic brain injury.  Up-
regulation of the intracerebral IL-18 gene occurs following TBI in mice254,255.  
IL-18 has been shown to induce intracellular expression of IL-1α, a precursor 
of IL-1β and IL-6 from mixed glia in the mouse. There is some evidence to 
suggest that IL-18 is modulated and can be inhibited by TNF-α, alluding to a 
possible dual function for the latter254. 
 
In ischaemia, there are conflicting reports as to whether regulation is actually 
induced in animal models, with some evidence for its late induction256,257.  
Mice lacking IL-18 were not protected in the early phase after ischaemia256.  
In neonatal hypoxic ischaemia, IL-18 showed an early increase, peaking at 14 
days with attenuation of brain injury seen in IL-18 deficient neonatal mice and 
rats252,258.  This protective effect was not noted in IL-1α and IL-1β deficient 
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mice, suggesting the importance of IL-18 in neonatal brain.  In a nested case-
control study, plasma IL-18 levels were not a predictor of recurrent ischaemic 
stroke226.  Contrary to this, plasma IL-18 was noted to be an independent 
predictor of 90-day major adverse clinical outcome in patients with ischaemic 
stroke259.  Furthermore, IL-18 functional promoter polymorphisms are 
associated with an increased risk of ischaemic stroke260. 
MCP-1 	  
MCP-1 is a member of the cysteine-cysteine chemokine gene family 
characterised by its chemoattractant properties for monocytes, memory T-
cells and natural killer cells in-vitro261.  Monocytes, smooth muscle cells, 
fibroblasts and vascular endothelial cells produce it in response to stimuli 
such as IL-1, TNF-α, interferon-γ and lipopolysaccaride262.   
 
MCP-1 is expressed in experimental models of ischaemia, with gene knockout 
animals lacking MCP-1 sustaining smaller infarct volumes and reduced 
monocyte and polymorphonuclear neutrophil infiltration compared to wild-
type263-268.  The relatively late change to cellular infiltration is unlikely to 
explain this protective effect.  An early reduction in IL-1β within ischaemic 
tissue was noted and may explain this protective effect265.  Similarly, 
overexpression of MCP-1 caused larger infarcts and greater chemoattraction 
of monocytes and macrophages into the ischaemic area269.  MCP-1 seemed 
to be necessary in recruiting blood-borne cells to the site of injury but did not 
seem to be involved in the microglia activation and migration that occurs 
during ischaemic injury266.   
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In clinical studies, MCP-1 was elevated 24 hours following ischaemic stroke in 
the CSF but the evidence for plasma elevation is conflicting224,270.  Plasma 
MCP-1 was an independent predictor of poor outcome as several early time 
points following ischaemic symptoms224.  Neuroblasts derived from the neural 
progenitors in the subventricular zone have been shown to migrate 
physiologically and during focal ischaemia268.  There is evidence to suggest 
that MCP-1 may be involved in attracting neuroblasts from the subventricular 
zone to the infarct268.   
 
In canine and rat models of SAH, MCP-1 was upregulated in vasospastic 
cerebral arteries and cerebral cortex271-273.  Sphingolipid 
sphingosylphosphorylcholine (SPC) is released by platelets and engages in a 
wide range of intracellular signalling pathways in different cell types274.  There 
has been a suggestion that SPC has a vasoconstrictor effect and pro-
inflammatory function in the cerebral vasculature.  SPC increased the release 
of MCP-1 in cultured vascular smooth muscle cells, implicating the latter in 
SPC-mediated pro-inflammatory effects274.  
Tumour necrosis factor-α 	  
The role of TNF-α in immunoactivation elicited in the brain has been subject 
to extensive investigation but is still unclear.  Following TBI, TNF-α has been 
detected in human CSF and plasma and is up-regulated in cerebral tissue in 
experimental models275.  TNF-α has been associated with activation of ICAM-
1, BBB dysfunction and intrathecal infiltration of activated leukocytes following 
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TBI275.  There is evidence largely from experimental knockout models that in 
addition to being a mediator of injury, TNF-α may confer protection275.  
Although there was no difference in the post-traumatic pathophysiology of 
knockout versus wild type animals (including intracerebral neutrophil 
infiltration and BBB permeability), increased mortality in certain knockout 
models would suggest a protective role for TNF-α following TBI275. 
 
TNF-α up-regulation was detected in brain autopsies after acute stroke276.  
CSF and plasma demonstrated significantly higher TNF-α levels in patients 
with ischaemic stroke within 24 hours of onset when compared with control277.  
In a nested case-control study, very high levels of plasma TNF-α were found 
to be a significant predictor of recurrent ischaemic stroke226.  TNF-α is also 
thought to release MMP-9217.  TNF-α appears to have different effects based 
on its intrinsic concentration and the relative contribution of 
synergistic/antagonistic cytokines. 
Vascular endothelial growth factor (VEGF) 	  
VEGF is an endothelial mitogen expressed in neuronal and vascular tissues in 
the brain.  VEGF may induce angiogenesis and increased vascular 
permeability.  It binds to a receptor tyrosine kinase to activate Sarcoma (Src) 
tyrosine kinase and mitogen-activated protein kinase (MAPK) pathways.  It 
has also been shown to stimulate neurogenesis278.  It is upregulated after 
experimental TBI and hypoxia, resulting in an increase in angiogenesis and 
vessel homeostasis278,279.  This has implications for the integrity of the BBB.  
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Conversely, blockade of its receptor has been shown to aggravate 
experimental brain trauma, suggesting a potentially protective role280. 
 
It has been implicated in the pathogenesis of aSAH.  MAPK pathway can be 
activated by various stimulants including VEGF281.  MAPK and VEGF are 
activated in the cerebral arteries and, to a lesser extent, in the cerebral cortex 
following experimental SAH282.  The resulting alterations in the BBB, 
enhanced brain oedema and death were attenuated by inhibition of the Src-
family tyrosine kinase, in addition to reducing VEGF expression.  This would 
implicate Src as both a downstream factor to VEGF receptor activation 
leading to MAPK, and an upstream factor involved in the signalling pathways 
that lead to VEGF activation. 
Anti-inflammatory mediators 	  
Interleukin-4 	  
IL-4 is a Th2-derived anti-inflammatory cytokine283,284.  IL-4 downregulates the 
release of pro-inflammatory cytokines from activated monocytes.  How IL-4 is 
involved in the regulation of immune responses in acute cerebrovascular 
disease is not known.  The number of blood mononuclear cells producing IL-4 
and plasma levels of IL-4 were not significantly different in acute stroke and 
neurological deterioration283,284.  In a mixed cohort of patients with TBI, aSAH 
and intracerebral haemorrhage, plasma IL-4 levels taken from the internal 
jugular vein were higher in patients that did not survive compared with those 
that survived the injury285.  Levels were inversely proportional to arterio-
jugular venous differences in oxygen content.  Local CNS evaluation of this 
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mediator and its evaluation specifically in the context of aSAH have not been 
previously documented.  
Interleukin-10 	  
In-vitro post-ischaemic microglial cells are thought to produce reactive oxygen 
species and cytotoxic cytokines such as TNF-α and IL-1β286.  In addition to 
this, they are thought to produce anti-inflammatory cytokines such as IL-10.  
IL-10 is also produced by T helper cells, macrophages, monocytes and B 
cells.  Its main target cell is the macrophage.  It is anti-inflammatory because 
it inhibits the production of cytokines from Th1 cells, the expression of cyclo-
oxygenase-2 and the production of TNF-α287.  There is some evidence to 
suggest that its neuroprotective properties are conferred by blocking caspase-
3 activity and reducing pro-inflammatory cytokine production288,289.  IL-6 and 
IL-10 negatively correlate with each other in normal subjects, indicating a 
balance between the pro-inflammatory and anti-inflammatory molecules287. 
 
In-vivo, over-expression of IL-10 markedly protected cortical tissue from 
ischaemia in transgenic mice290.  A similar neuroprotective effect was noted 
following spirochetal brain infection in mice291.  IL-10 deficiency resulted in 
early death from subarachnoid/intraparenchymal haemorrhage following 
infection.  This was also associated with apoptosis of brain microvascular 
endothelial cells and increased systemic production of TNF-α.  Conversely, 
post-ischaemic gene transfer of IL-10 into the rat focal and global ischaemia 
model attenuated brain infarction and hippocampal damage292.  
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It is unclear what happens to IL-10 levels following brain trauma and 
ischaemia in humans.  Intracerebral haemorrhage has been shown to be 
associated with elevated plasma IL-10 levels (taken within 48 hours of 
haemorrhage)221.  There are conflicting reports in stroke patients of both 
increased and decreased plasma IL-10 levels and number of IL-10 secreting 
cells222,223,284,287,293.  Similarly, there have been mixed reports at to whether IL-
10 levels are associated with poor outcome following ischaemic 
stroke223,287,293,294.  Elderly patients with a history of stroke were shown to 
have a significantly lower plasma IL-10295.  The risk of fatal stroke during the 
prospective study period was higher in those with low or intermediate baseline 
IL-10 production levels.  IL-10-1082 G/A, promoter polymorphism is 
associated with lower IL-10 production and ischaemic stroke in a south Indian 
population296.  This would suggest that following ischaemic stroke, there may 
be an anti-inflammatory cascade that combats the disease process and a 
genetic predisposition resulting in a weaker response maybe detrimental to 
outcome.  This is supported by the finding that in acute ischaemic brain injury, 
IL-10 was an independent predictor of stroke-associated infection297.  This 
suggests that a blood-borne anti-inflammatory response is initiated following 
ischaemic stroke that decreases microbial resistance in the immune system.  
This has been noted in other disease states298.  IL-10 dampens TNF-α-
mediated inflammation during bacterial infection.  The presence or absence of 
IL-10 in infected tissue dictates the strength of the immune response but also 
the amount of apoptosis incurred due to inflammation (figure 3). 
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Figure 3-The balance between apoptosis and pathogen persistence.  A heavily inflamed 
apoptotic environment is not conducive to pathogen survival.  Some pathogens induce 
interleukin (IL-10) via pattern recognition receptors to subvert the development of acute 
inflammation.  An abundance of IL-10 decreases activation-induced inflammation and 
apoptosis allowing pathogen persistence intracellularly.  Conversely, if IL-10 is not induced, 
robust inflammation develops leading to high levels of apoptosis and parenchymal damage.  
Source: Cyktor et al., 2011, Infection and Immunity298. 
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Inflammation following aSAH 	  
Cytokines in aSAH 	  
There is increasing evidence to suggest that a complex inflammatory 
response is initiated both systemically and within the CNS following aSAH.  
How this relates to ischaemic neurological injury and which exact mediators 
and mechanisms are involved is currently unclear.  Numerous clinical studies 
have investigated the association between aSAH, DIND and cytokine 
production219,299-312.  The most widely investigated mediators include 
interleukin (IL)-1α, IL-1β, TNF-α, IL-6 and IL-8 (Table 8).  Although these 
mediators are generally detected in higher than normal concentrations in CSF 
following aSAH, there is some evidence to suggest that increases in CSF IL-6 
may be specifically associated with radiological vasospasm and 
DIND219,306,311,313.  CSF IL-6 levels were significantly higher on days 4 and 5 
following haemorrhage.  These changes often preceded clinical signs of 
DIND, thus giving IL-6 predictive power for the onset of DIND, with a 
significant correlation between IL-6 levels and DIND on day 7219,306.  Serum 
and CSF concentrations of MCP-1 were significantly higher following aSAH 
than in controls undergoing surgery for an unruptured aneurysm262.  Serum 
and CSF concentrations of MCP-1 were associated with poor outcome and 
angiographic vasospasm respectively.  
 
In recent years, microdialysis has become an established method for 
biochemical surveillance of patients in the neurointensive care setting.  
Catheters with a high molecular weight cut-off have been developed to allow  
Table 8-Summary of clinical studies investigating inflammatory mediators following aSAH. * indicates significance at p=0.05 
Abbreviations: aSAH-aneurysmal subarachnoid haemorrhage, IL-interleukin, CD-cluster of differentiation, CSF-cerebrospinal fluid, DIND-delayed ischaemic 
neurological deficit, TNF-tumour necrosis factor, IL-1ra-interleukin-1 receptor agonist. 
Study No of 
patients 
Mediators 
investigated 
Compartment 
(plasma/CSF) 
Key findings (* statistical significance) Association with DIND (*statistical 
significance) 
Mathiesen et al., 
1993 
8 aSAH IL-6, IL-2, 
CD-8 
Plasma & CSF ↑CSF IL-6* Levels peaked on day 6. Higher in 
DIND. Not paralleled by plasma levels. 
Kikuchi et al., 
1995 
7 aSAH IL-1α&β, IL-6, 
IL-8, TNF-α 
Plasma & CSF CSF and plasma IL-6 & IL-8 detected. CSF level 
> plasma level 
None 
Mathiesen et al., 
1997 
22 aSAH 
10 Controls 
IL-1ra, TNF-α CSF Both were higher than normal controls. 
Increased in those with eventual poor outcome. 
IL-1ra was increased during DIND 
Osuka et al., 
1998 
9 aSAH 
9 Controls 
IL-6, IL-8, IL-
1β 
Plasma & CSF ↑CSF IL-6/IL-8*, > plasma level. IL-1β no 
change. 
↑CSF IL-6 & IL-8 in those with DIND* 
Gaetani et al., 
1998 
31 aSAH 
10 Controls 
IL-6, IL-8 CSF ↑IL-6/IL-8* for those operated within 72 hours. ↑IL-6 in those with DIND* 
Kwon et al., 
2001 
19 aSAH 
12 Controls 
IL-1β, TNF-α, 
IL-6 
CSF Only levels within 24 hours investigated.  IL-1β 
& TNF-α higher compared to controls*. 
↑ IL-1β & TNF-α in those with DIND 
↑IL-6 in those with DIND* 
Fassbender et 
al., 2001 
35 aSAH 
20 Controls 
IL-1β, TNF-α, 
IL-6 
Plasma & CSF ↑CSF IL-1β, TNF-α & IL-6*.  Peaking at days 5 
to 9.  Paralleled by plasma levels in TNF-α only.   
Not commented upon. 
Schoch et al., 
2007 
64 aSAH IL-6 CSF ↑ CSF IL-6 overall*, individual variability evident. IL-6 on days 4/5 predicted DIND. 
measurement of cytokines and other macromolecules from the extracellular 
space of the brain.  Serial measurements of IL-6 in plasma, CSF and the 
extracellular fluid (ECF) using microdialysis following aSAH demonstrated that 
the highest concentration was found in the CSF followed by the ECF and 
plasma respectively313.  All compartments demonstrated significantly higher 
levels than normal controls312,313.  Both ECF and CSF IL-6 were predictive of 
DIND312.  For those patients with elevated ICP, IL-6 increased in the ECF and 
decreased in the CSF after four days post-ictus313.  During this time, plasma 
IL-6 and other systemic markers of inflammation were elevated.  This state 
was also associated with a poor outcome.  Although the results are 
conflicting, overall evidence favours intrathecal cytokine production, such that 
increases in CSF/ECF are not paralleled in plasma, highlighting the 
compartmentalisation of this process.  How the CSF and ECF levels are 
related is unclear.  Although high cut-off membranes have the potential to 
expand microdialysis to the study of protein chemistry, there are numerous 
difficulties with their use and in the interpretation of the results obtained314. 
 
Adhesion molecules and aSAH 
 
Several studies have demonstrated an association between soluble adhesion 
molecule levels and markers of endothelial cell activation following aSAH and 
DIND315-320.  Von Willebrand Factor (vWF) is a blood glycoprotein involved in 
haemostasis and is one such marker of endothelial cell activation.  Levels of 
vWF measured within 72 hours of haemorrhage were slightly raised and 
weakly associated with subsequent DIND315,316, which was thought to be an 
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acute response reflecting haemorrhage severity and thus subsequent delayed 
complications.  Serial measurements also demonstrated that soluble P-
selectin increased significantly in patients with DIND (in contrast to those 
without, where levels decreased)315,316,320.  Although an association between 
ICAM-1 and poor neurological outcome has been made317,319, this has not 
been consistently associated with DIND315,316,320.   
 
Genetic predisposition 	  
Genetic predisposition to inflammation following aSAH has been subject to 
some investigation.  Although polymorphisms of IL-1β (-511) genotype were 
not associated with aSAH per se, carrying a T/T genotype was associated 
with a poor aSAH grade and poor 6-month outcome321.  There are mixed 
reports as to whether IL-6 gene polymorphisms are associated with both 
ruptured and unruptured intracranial aneurysms322,323.  Patients with aSAH 
exhibiting the TNF-α non-wild type allele resulting in a lower serum TNF-α 
concentration had a higher risk of poor outcome324.  
 
To test the hypothesis that DIND occurs in some people and not in others 
because of the variation in the inflammatory response that occurs between 
individuals, the relationship between immune activation and DIND following 
aSAH was investigated325.  Northern hybridization was utilised to evaluate the 
expression of IL-1β and TNF-α in cultured monocytes from patients with 
aSAH.  Activation indices for TNF-α were high in all cases and showed 
individual variation for IL-1β.  This variation correlated significantly with 
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angiographic vasospasm of the anterior cerebral artery only.  Those with 
DIND showed significantly higher activation indices than those without.   
 
Cellular infiltration and systemic inflammation in aSAH 	  
Based on both animal and clinical studies, a three-step inflammatory process 
has been suggested to occur following aSAH, which may be associated with 
DIND.  The three-step model begins with an unidentified signal within the 
subarachnoid space that initiates a cascade of molecular events leading to an 
upregulation of ICAM-1204.  Leukocytes then interact with endothelial selectins 
via their sialylated carbohydrates, resulting in their tethering and rolling along 
the endothelium.  Leukocyte arrest is initiated when an integrin interacts with 
endothelial ICAM-1.  Subsequently, leukocytes migrate through the vessel 
wall and are thought to mediate ischaemic brain injury, although endothelial 
cell activation has also been implicated in this process326.   
 
Early studies correlated DIND with a raised systemic temperature following 
aSAH327,328.  A fever curve beginning on the fifth day following haemorrhage 
was noted in 88% of patients with DIND versus 18% without327.  Patients with 
DIND have also been noted to have a higher peripheral white cell count329-332, 
with a peak leukocyte count greater than 15 X 109/L increasing the odds of 
DIND three-fold333.  There have been several studies demonstrating the 
presence of circulating immune complexes and complement activation in 
patients with angiographic vasospasm and DIND334,335.  Immune complex 
deposits and cellular infiltration have been demonstrated in the arterial media 
of cerebral blood vessels following aSAH325.  Following aSAH, an increase in 
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lymphocyte sub-populations within the CSF occurs in those with DIND, 
particularly intrathecal suppressor/cytotoxic/NK-cells336. 
 
There is evidence to suggest that early activation of the systemic 
inflammatory response syndrome (SIRS) occurs following aSAH in most 
patients337,338.  SIRS represents a collection of clinical findings originally 
described in association with sepsis that is thought to arise as a result of 
cytokine or circulating catecholamine release, which promotes immune 
activation339.  SIRS has been associated with poor clinical grade, thick 
cisternal blood, large aneurysm size, surgical aneurysm treatment and 
hypertension337, and the magnitude of this response is an independent 
predictor of DIND and poor outcome but not of angiographic vasospasm.  
However, the interpretation of this study is limited by its retrospective analysis 
of prospectively collected data, its investigation of a complex, multifactorial 
physiological response and lack of standardisation of corticosteroid regimens. 
 
The complement cascade is a principal effector of erythrocyte haemolysis and 
activator of inflammatory mediators.  Early studies demonstrated an 
association between circulating/CSF immune complexes and complement 
components, and the development of angiographic vasospasm and DIND340-
342.  Plasma C3a and C5a were shown to be elevated following aSAH when 
compared with normal controls, while early C3a levels were independently 
associated with outcome343.   
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Summary 	  
Both systemic and compartmentalised inflammatory/immune responses 
following aSAH have been associated with DIND, although causality is less 
clear.  Investigating the systemic component is complicated by numerous 
confounding causative factors and endpoints that are difficult to quantify.  
Does this systemic inflammatory response truly contribute to DIND or is this 
an epiphenomenon related only to the severity of the aSAH as measured by 
clinical grade and blood volume load?  A large prospective study is required to 
determine this and account for confounding factors during regression 
modelling.  Similarly, investigating the CNS inflammatory response is 
complicated by that observed following ischaemia in ischaemia/reperfusion 
models133.  Is CNS inflammation a cause or a consequence of DIND?  
Measurement of inflammatory mediators in blood, CSF and brain ECF is 
technically difficult and is subject to variability between patients and their 
courses following aSAH, regardless of the development of DIND.  Clinical 
studies utilising various anti-inflammatory agents such as cyclosporin and 
methylprednisolone have unsurprisingly been disappointing344, highlighting 
that inflammation following aSAH is pleiotropic and multifaceted.  New studies 
utilising specific interleukin antagonists and antibodies to block leukocyte-
endothelial interactions are awaited.  
 	    
Aims of the study 
 
The aim of the current study is to answer the following questions: 
1. Do plasma and CSF cytokine levels change following aSAH?   
2. If so, do plasma and CSF levels correlate with each other and to what extent 
is this response compartmentalised within the central nervous system?   
3. Are there any changes associated with DIND?   
4. If so, what is the time course for these changes in relation to ictus of 
haemorrhage and do these markers hold predictive characteristics?   	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Materials and methods 
 
Patients 	  
Patients with aSAH recruited into the lumbar drain trial were eligible for this 
secondary study.  Ethical approval was obtained by the Leeds (West) 
Research Ethics Committee.  Control non-aSAH patients were recruited after 
obtaining written informed consent as part of a separate ethical approval 
obtained by the Bradford Research Ethics Committee.   
 
Procedure and Interventions 
 
Patients that present with aSAH were assessed for eligibility for inclusion into 
the lumbar drain trial (see above).  As part of the consent/assent process, 
permission was obtained to collect and store plasma and CSF.  These were 
collected at certain time-points following the presumed time of ictus (taken as 
time=0).  Once aneurysmal pathology had been confirmed and 
consent/assent was obtained, the first blood and CSF samples were 
collected.  Samples of plasma and CSF were collected simultaneously and at 
9am where possible.  In the event of randomisation into the control group, 
only plasma was obtained (due to lack of accessible CSF). 
 
Venous blood was taken from the antecubital fossa and drawn into EDTA 
containers.  CSF was removed from the lumbar drain using an aseptic 
technique.  The first 2 ml of CSF drawn from the drain was discarded, as this 
would represent the dead space volume of the lumbar drain.  Subsequently 
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drawn CSF was utilised for analysis.  Both blood and CSF samples were 
immediately placed on ice and centrifuged at 3000 rpm for 15 minutes (at 
room temperature).  The supernatant was removed and stored at -80oC until 
further analysis. 
 
Fixed time points for sampling were at days 5, 7 and 9 following ictus where 
possible.  Due to the variability associated with when patients present to our 
unit in relation to time of ictus, the first sample was taken at a variable time 
point defined as within 96 hours of ictus and within 12 hours following 
intervention (endovascular or surgical).  Additional time points that were 
collected include at the time of onset of DIND.  Occasionally patients were 
discharged from the neurosurgery department before day 9 or lumbar 
drainage was stopped prior to retrieval of all samples.  As a minimal 
requirement, at least the initial sample and days 5 and 7 were required to be 
included in this study. 
 
There were four cohorts of aSAH patients.  For each arm of the trial, some 
patients developed DIND and others did not.  Therefore the cohorts of aSAH 
patients are: 
Group 1: Lumbar drainage with DIND 
Group 2: Lumbar drainage without DIND   
Group 3: Control with DIND 
Group 4: Control without DIND 
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Both CSF and plasma were available for groups 1 and 2, whereas only 
plasma was available for groups 3 and 4.   
 
A control group of normal subjects (non-aSAH) were also sampled (group 5).  
This group consisted of patients undergoing elective surgery requiring spinal 
anaesthesia (hip and knee replacements).  
 
Exclusions 	  
Patients with aSAH that developed clinical and biochemical signs of 
sepsis/infection were excluded from the analysis.  Patients in group 5 that 
were undergoing elective joint replacement due to rheumatoid arthritis were 
also excluded from the analysis. 
 
Molecular analysis 	  
Assay format 	  
Analysis was performed using the Bio-Plex® suspension array system 
manufactured by Biorad® as previously described 345.  This system is built 
around the three core elements: 
1. Fluorescently dyed microspheres (also called beads), each with a distinct 
spectral address.  This allows simultaneous detection of more than 100 
different types of molecules in a single well of a 96-well microplate. 
2.  A dedicated flow cytometer with two lasers and associated optics to 
measure the different molecules bound to the surface of the beads. 
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3.  A high-speed digital signal processor that efficiently manages the 
fluorescence data. 
The assays are immunoassays formatted on magnetic beads similar to a 
sandwich enzyme-linked immunosorbent assay (ELISA) (Figure 4).  Capture 
antibodies directed against the desired biomarker are covalently couples to 
the beads, which react with 
 
Figure 4-Bio-Plex sandwich immunoassay  
 
 
the sample containing the biomarker of interest.  A series of washes removes 
the unbound protein and a biotinylated detection antibody is added to create a 
sandwhich complex.  Streptavidin-phycoerythrin (PE) conjugate is added to 
form the final detection complex (the latter serving as a fluorescent indicator). 
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Data acquisition and analysis 	  
The data was acquired with a Luminex-100 cytometer.  The assay suspension 
was drawn into the reader and a red (635 nm) laser illuminates the fluorescent 
dyes within each bead to provide a bead classification.  This identifies the 
target analyte.  Simultaneously, a green (532 nm) laser excites the PE part of 
the conjugate to generate a reporter signal that is detected by a 
photomultiplier tube (PMT).  Bio-Plex Manager TM software presents data as 
Median Fluorescence Intensity (MFI) as well as concentration (picograms 
(pg)/ml).  The concentration of analyte bound to each bead is proportional to 
the MFI.  A calibration curve was used to obtain the concentration in pg/ml. 
Plate preparation 	  
The plate layout was planned and labelled.  Assay reagents were equilibrated 
to room temperature.  The samples were removed from the freezer and 
allowed to thaw.  The wash station was primed and the system was 
calibrated.  The 96-well filter plate was washed via vacuum filtration using a 
vacuum manifold.   
 
Figure 5 shows a typical sample plate layout.  In the 96-well filter, columns 1 
and 2 are assigned to the calibration curve standards.  Two wells were 
assigned as blanks, which consisted of standard diluent (serum-based matrix 
that mimics the matrix in 1:4 diluted samples).  The Bio-Plex ManagerTM 
software automatically subtracted the assay blank FI value from the standard 
and sample Fl values.   
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Standards preparation 	  
A single vial of standards was reconstituted in 500 µl of the standard diluent.  
This was vortexed and incubated on ice for 30 minutes.  An eight point 
standard dilution series was prepared and blanked.  The lyophilized standard 
was gently tapped to ensure the pellet is at the bottom of the vial.  500 µl of 
the standard diluent were used to reconstitute the standard.  This was gently 
vortexed for 1-3 seconds and incubated on ice for 30 minutes. 
 
The following dilution series produced an eight-point standard curve with a 
four-fold dilution between each point.  New pipette tips were used for every 
volume transfer.  Nine 1.5 ml tubes were labelled S1 through to S8 and Blank.  
Diluent was added to tube S1 (72 µl) and tubes S2-8 (150 µl).  Figure 6 
demonstrates the steps in the serial dilution.  The reconstituted standards 
were gently vortexed for 1-3 seconds prior to removal of any volume.  128 µl 
of the standard were added to S1.  50 µl were transferred from S1 to S2.  This 
was continued for the remaining tubes as illustrated in Figure 6.  Samples 
were vortexed throughout each step of the serial dilutions. 
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Figure 5-Plate formatting 
	  
	  
	  
 
 
Figure 6-Preparing a fourfold dilution series with a single reconstituted standard 
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Sample preparation 	  
Once the samples were thawed, they were centrifuged at 1000 x g for 15 
minutes and the plasma and CSF transferred to a clean polypropylene tube.  
Dilution with Bio-plex sample diluent by the order of 1:4 was performed by 
adding 1 volume of sample to 3 volumes of sample diluent.  The first analysis 
consisted of five wells dedicated to CSF samples in order to confirm that this 
dilution was appropriate for this biological fluid. 
 
Preparation of coupled beads 	  
The coupled beads were prepared in assay buffer whilst being protected from 
light.  The volume of coupled beads was calculated as follows: 
1. Each well required 50 µl of 1x coupled beads.   
2. For 96 wells, this required 4800 µl total volume. 
3. As 20% excess was included to ensure enough volume: 960 µl 
4. Total volume of 1x coupled beads: 5760 µl 
5. Volume of 20x coupled beads stock: 5760/20 = 288 µl 
6. Volume of assay buffer required: 5760 – 288 = 5472 µl 
 
The assay buffer was placed into a 15 ml universal tube.  The coupled beads 
were vortexed at mid speed for 30 seconds.  The required volume of 20x 
stocked coupled beads was pipetted into the polypropylene tube with the 
assay buffer.  The beads were protected from light with aluminium foil while 
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they were allowed to equilibrate at room temperature for 20 minutes prior to 
use to prevent their photobleaching. 
Wash and incubation 	  
All buffers, diluted standards, diluted coupled beads and samples were 
brought to room temperature prior to the assay run.  Repeated washes and 
incubations on shaker procedures were required.  This consisted of: 
1. The filter assay plate was placed on a calibrated vacuum apparatus and the 
buffer was removed by vacuum filtration.  100 µl of wash buffer was added to 
each well and the contents aspirated by vacuum filtration.  The bottom of the 
filter plate was thoroughly blotted with a clean paper towel between each 
vacuum step to prevent cross contamination and plate leakage. 
2.  The plate was covered with a new sheet of sealing tape and placed on a 
microplate shaker and covered with aluminium foil to prevent photobleaching.  
It was shaken at room temperature at 1100 rpm for 30 seconds and then at 
300 rpm for the incubation time. 
Addition of coupled beads, standards and samples 	  
The filter plate was prewetted with 100 µl assay buffer and the liquid was 
removed by vacuum filtration.  The bottom of the filter plate was thoroughly 
blotted on a clean paper towel.  The diluted coupled beads were vortexed for 
30 seconds at medium speed and the beads poured into a reagent reservoir.  
50 µl were added to each well using a multichannel pipette.  The wells were 
subsequently washed twice as described above. 
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The diluted standards, blanks, samples and controls were gently vortexed for 
1-3 seconds and 50 µl of diluted standard, control and sample were added to 
each well.  The plate is subsequently incubated on shaker at room 
temperature for 30 minutes. 
Preparation and addition of detection antibodies 	  
The volume of detection antibodies was determined as follows: 
1.  Each well required 25 µl detection antibodies (1x).  For 96 wells this was a 
total volume of 2400 µl. 
2.  A 25% excess to ensure enough volume was also included: 600 µl leaving 
a total volume of 1x detection antibodies: 3000 µl. 
3.  Volume of 20x detection antibodies stock: 150 µl. 
4.  Volume of detection antibody diluent required: 2850 µl. 
This volume of detection antibody diluent was added to a 15 ml tube.  The 
detection antibodies were vortexed for 15-20 seconds at medium speed 
followed by a 30 second spin to collect the entire volume at the bottom of the 
vial.  For each detection antibody, the required volume (150 µl) was pipetted 
into a 15 ml polypropylene tube.  Each well of the assay required 1.25 µl of 
20x detection antibody adjusted to a final volume of 25 µl. 
 
After incubating the samples, the sealing tape was slowly removed and 
discarded.  The plate was washed three times as described above.  The 
diluted detection antibodies were vortexed for 1-3 seconds and poured into a 
reagent reservoir.  25 µl were added to each well using a multichannel pipette.  
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The plate was covered with a new sheet of sealing tape and the wells sealed.  
The plate was incubated on shaker at room temperature for 30 minutes.   
Preparation and addition of Streptavidin-PE 	  
The volume of streptavidin-PE and assay buffer were calculated as follows: 
1.  Each well required 50 µl of 1x streptavidin-PE: 4800 µl 
2.  25% excess to ensure enough volume: 1200 µl 
3. Total volume of 1x streptavidin-PE required: 6000 µl 
4.  Volume of 100x streptavidin-PE required: 60 µl 
5.  Volume of assay buffer required: 5940 µl 
 
This assay buffer was added to a 15 ml tube.  The streptavidin-PE tube was 
vortexed for 15-20 seconds at medium speed followed by a 30 second spin to 
collect the entire volume at the bottom of the vial.  The required volume of 
stock streptavidin-PE was pipetted into a 15 ml polypropylene tube containing 
the assay buffer in order to dilute the streptavidin-PE to a 1x concentration.   
 
After detection antibody incubation, this was slowly removed and the sealing 
tape discarded.  The plate was washed three times and the diluted 
streptavidin-PE was vortexed at medium speed for 3-5 seconds.  This was 
poured into a reagent reservoir and 50 µl were added to each well using a 
multichannel pipette.  Incubation on shaker was performed at room 
temperature for 10 minutes. 
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After the streptavidin-PE incubation step, the wells were washed three times.  
125µl assay buffer was added to each well and the plate covered with a new 
sheet of sealing tape.  The plate was shaken at room temperature at 1100 
rpm for 30 seconds. 
Plate reading and data acquisition 	  
A protocol file specifying the analytes used in the reading, the plate wells to 
be read, the sample information, the values of the standards and controls, 
bead region number and instrument settings was prepared in advance using 
the Bio-Plex Manager 6.0 software as shown in table 10.  The wells were 
defined as shown in figure 5. 
 
To enter the standards, the highest concentration of each analyte was entered 
into the top row (labelled S1) of the table.  A dilution factor of 4 was entered 
and the concentration for each standard point was populated in the table by 
the software.  The assay plate was shaken at 1100 rpm for 30 seconds and 
the sealing tape is removed prior to placing the plate in the plate reader.  The 
protocol was subsequently run.   
 
Specifications of assay 	  
The manufacturer’s specification list is as follows: 
Sensitivity ≈ 10 pg/ml (based on detectable signal >2 SD above background). 
Precision: Inter-assay CV: <30%; intra-assay CV: <20% 
Cross-reactivity: Negligible 
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Table 10-Cytokine assay bead regions 
 
Abbreviations: IL-interleukin, MCP-monocyte chemotactic protein, TNF-tumour necrosis 
factor, VEGF-vascular endothelial growth factor. 
Cytokine Bead Region Group 
IL-1β 39 1 
IL-4 52 1 
IL-6 19 1 
IL-8 54 1 
IL-10 56 1 
IL-15 73 1 
IL-17 76 1 
MCP-1 53 1 
TNF-α 36 1 
VEGF 45 1 
IL-1α 63 2 
IL-18 42 2 
	  
 
Statistical analysis 	  
All analyses were performed in duplicate with mean values analysed.  The 
spread of data for aSAH patients was investigated in order to highlight and 
exclude extreme values greater than 2 standard deviations from the mean.  
All day 9 CSF samples were removed from the analysis due to a very small 
sample size (n<5).  All mediator data was tested for normality with the 
Shapiro-Wilks test and Q-Q plots.  Time serial analyses were performed using 
one-way analysis of variance (ANOVA) with Games-Howell post hoc analysis 
at a significance level of 0.05.  Comparison of DIND and non-DIND data was 
performed with the independent t-test and Mann-Whitney-U test for 
parametric and non-parametric data respectively.  A further sub-group 
analysis of the distribution of when DIND was diagnosed was not possible due 
to small sample sizes.  Independent t-tests were conducted with Levene’s test 
for equality of variances.  Binary logistic regression analysis was performed 
with MRS at day 10 and 6 months post ictus as the outcome variable (MRS 3-
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6 considered as poor outcome).  All mediators were forced into the model.  
Any mediators identified as significant predictors were placed into a second 
model as a second step following age, WFNS and Fisher grade placement.  p 
< 0.05 was considered statistically significant.  All statistical tests were 
performed with IBM SPSS version 18 (and StataCorp STATA for the Games-
Howell analysis). 
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Results 
 
Cohort demographics 	  
Table 11 demonstrates the clinical characteristics of this cohort of aSAH 
patients. 
 
Table 11-Cohort characteristics 
Abbreviations: aSAH-aneurysmal subarachnoid haemorrhage, WFNS-World Federation of 
Neurological Surgeons. 
 Patients with 
aSAH 
Control patients 
Number of patients 43 12 
Median age/years 
(interquartile range) 
58 (48-63) 65 (52-68) 
Male : female 1 : 2.9 1 : 2 
WFNS grade 1 32 N/A 
2 10 N/A 
3 1 N/A 
Fisher grade 2 10 N/A 
3 26 N/A 
4 1 N/A 
3 + 4 6 N/A 
Aneurysm 
treatment 
Coiling 27 N/A 
Clipping 11 N/A 
Both 5 N/A 
 
Plasma 
 
Time serial analysis and control comparison 
Figure 7 demonstrates box plots of the plasma mediator levels at each time-
point following aSAH.  Compared to controls, significantly higher levels were 
noted in the plasma for IL-6, IL-8 and IL-15 at days 3, 5 and 7.  No other 
significant differences were noted. 
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Comparison of DIND and non-DIND 	  
Figure 8 demonstrates mediator levels at each time-point for DIND and non-
DIND patients.  IL-10 was significantly lower in patients with DIND at day 3 
(p=0.031).  There was a trend for lower mediator levels in DIND patients in IL-
1β, IL-10, IL-15 and TNF-α at all time-points although this did not reach 
statistical significance. 
 
Comparison of DIND samples on the day of clinical symptoms with non-
DIND patients 	  
Figure 9 demonstrates a comparison of plasma mediator levels of DIND 
patients (on the day of commencement of DIND) with mediators taken from 
non-DIND patients at other time points.  The analysis did not show any 
significant differences between DIND levels and non-DIND patients at all time-
points.  There was a tendency for day 9 plasma samples to show elevated 
mediator levels for all patients with a larger spread of data.  Day 9 sample 
numbers were small for this analysis (n=4). 
 
Logistic regression analysis 	  
With ten-day MRS placed as the outcome variable, the regression analysis for 
mediators at day 3 revealed IL-18 to be a significant predictor of poor 
outcome (odds ratio (OR) 0.91, CI 0.83-0.99, p=0.031).  This significance was 
lost in the second model when age, WFNS grade and Fisher grade were 
accounted for (OR 0.96, CI 0.92-1.004, p=0.074).  At day 5, IL-1α was a 
significant predictor of poor outcome (OR 113, CI 1.1-11888, p=0.047).  This 
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significance was lost in the second model (OR 5.9, CI 0.34-101, p=0.22).  At 
day 7, IL-1α (OR 65.9, CI 1.1-4103, p=0.047), IL-18 (OR 0.93, CI 0.88-0.996, 
p=0.037), IL-4 (OR 0.03, CI 0.001-0.80, p=0.036) and IL-6 (OR 1.24, CI 1.03-
1.49, p=0.021) were significant predictors of poor outcome.  This significance 
was lost in the second model. 
Figure 7: Box plots demonstrating median plasma mediator concentrations.  Interquartile range 
and extreme values are highlighted (ο and * denote greater than two and three lengths of the box 
respectively, values greater than 3 standard deviations have been excluded).  Units are pg/ml.  Values 
are given at days 3, 5, 7 and 9-post haemorrhage.  Control values are also shown.  Comparisons are 
between each time-point and control values; * denotes p<0.05, ** denotes p<0.01, *** denotes 
p<0.001.  Abbreviations: IL-interleukin, MCP-monocyte chemotactic protein, TNF-tumour necrosis 
factor, VEGF-vascular endothelial growth factor. 
 
Figure 8-Box plots demonstrating median plasma mediator concentrations.  Interquartile range 
and extreme values are highlighted (ο and * denote greater than two and three lengths of the box 
respectively, values greater than 3 standard deviations have been excluded).  Units are pg/ml.  Values 
are given at days 3, 5, 7 and 9-post haemorrhage for both DIND and non-DIND patients.  Control 
values are also shown.  Comparisons are between DIND and non-DIND; * denotes p<0.05, ** denotes 
p<0.01, *** denotes p<0.001.  Abbreviations: IL-interleukin, MCP-monocyte chemotactic protein, TNF-
tumour necrosis factor, VEGF-vascular endothelial growth factor, DIND-delayed ischaemic 
neurological deficit. 
 
Figure 9-Box plots demonstrating median plasma mediator concentrations.  Interquartile range 
and extreme values are highlighted (ο and * denote greater than two and three lengths of the box 
respectively, values greater than 3 standard deviations have been excluded).  Units are pg/ml.  Values 
are given at days 3, 5, 7 and 9-post haemorrhage for non-DIND patients and values on the day of 
commencement of symptoms in those with DIND.  Control values are also shown.  Abbreviations: IL-
interleukin, MCP-monocyte chemotactic protein, TNF-tumour necrosis factor, VEGF-vascular 
endothelial growth factor, DIND-delayed ischaemic neurological deficit. 
With six-month MRS placed as the outcome variable, no significant predictors 
of outcome could be found from the mediators. 
 
CSF 
 
Time serial analysis and control comparison 	  
Figure 10 demonstrates box plots of the CSF mediator levels at each time-
point following aSAH in addition to control values.  There is a significant 
increase in CSF IL-1α, IL-1β, IL-4, IL-6, IL-8 and TNF-α levels between day 3 
and day 5.  Levels of IL-18, IL-1β, IL-4, IL-6, IL-8, IL-15, IL-17, MCP-1, TNF-α 
and VEGF were significantly higher than controls on days 3, 5 and 7.  IL-10 
was significantly higher than controls on days 5 and 7 only. 
 
Comparison of DIND and non-DIND 	  
Figure 11 demonstrates mediator levels at each time-point for DIND and non-
DIND patients.  Although there was a trend of higher CSF levels in DIND 
patients at all time-points for IL-1β, IL-4, IL-17, TNF-α and VEGF, this was 
only statistically significant for VEGF on day 5 (p=0.033). 	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Comparison of DIND samples on the day of clinical symptoms with non-
DIND patients 
 
Figure 12 demonstrates a comparison of CSF mediator levels of DIND 
patients (on the day of commencement of DIND) with mediators taken from 
non-DIND patients at other time points.  DIND values were significantly higher
Figure 10-Box plots demonstrating median CSF mediator concentrations.  Interquartile range 
and extreme values are highlighted (ο and * denote greater than two and three lengths of the box 
respectively, values greater than 3 standard deviations have been excluded).  Units are pg/ml.  Values 
are given at days 3, 5, 7 and 9 post-haemorrhage.  Control values are also shown.  Comparisons are 
between each time-point; * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001.  Comparisons 
between each time-point and control values are shown in blue; * denotes p<0.05, ** denotes p<0.01, 
*** denotes p<0.001.  Abbreviations: IL-interleukin, MCP-monocyte chemotactic protein, TNF-tumour 
necrosis factor, VEGF-vascular endothelial growth factor. 
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Figure 11-Box plots demonstrating median CSF mediator concentrations.  Interquartile range 
and extreme values are highlighted (ο and * denote greater than two and three lengths of the box 
respectively, values greater than 3 standard deviations have been excluded).  Units are pg/ml.  Values 
are given at days 3, 5, 7 and 9-post haemorrhage for both DIND and non-DIND patients.  Control 
values are also shown.  Comparisons are between DIND and non-DIND; * denotes p<0.05, ** denotes 
p<0.01, *** denotes p<0.001.  Abbreviations: IL-interleukin, MCP-monocyte chemotactic protein, TNF-
tumour necrosis factor, VEGF-vascular endothelial growth factor, DIND-delayed ischaemic 
neurological deficit. 
 
Figure 12-Box plots demonstrating median CSF mediator concentrations.  Interquartile range 
and extreme values are highlighted (ο and * denote greater than two and three lengths of the box 
respectively, values greater than 3 standard deviations have been excluded).  Units are pg/ml.  Values 
are given at days 3, 5, 7 and 9 post-haemorrhage for non-DIND patients and values on the day of 
commencement of symptoms in those with DIND.  Control values are also shown.  Comparisons are 
between DIND values and non-DIND values at all time-points; * denotes p<0.05, ** denotes p<0.01, 
*** denotes p<0.001.  Abbreviations: IL-interleukin, MCP-monocyte chemotactic protein, TNF-tumour 
necrosis factor, VEGF-vascular endothelial growth factor, DIND-delayed ischaemic neurological 
deficit. 
Logistic regression analysis 	  
No significant predictors of 10-day or 6-month MRS were found amongst the 
mediators in CSF. 
 
Comparison of plasma and CSF levels 	  
Figure 13 demonstrates box plots comparing plasma and CSF levels of each 
mediator at all time-points and in controls.  All levels were significantly higher 
in the CSF apart from IL-1α and IL-18, which were higher in the plasma.  No 
markers demonstrated changes in the plasma that were mirrored by CSF 
levels. 
 
Figure 13-Box plots demonstrating median plasma and CSF mediator concentrations.  
Interquartile range and extreme values are highlighted (ο and * denote greater than two and three 
lengths of the box respectively, values greater than 3 standard deviations have been excluded).  Units 
are pg/ml.  Values are given at days 3, 5, 7 and 9 post-haemorrhage.  Control values are also shown.  
Comparisons are between plasma and CSF at all time-points; * denotes p<0.05, ** denotes p<0.01, 
*** denotes p<0.001.  Abbreviations: IL-interleukin, MCP-monocyte chemotactic protein, TNF-tumour 
necrosis factor, VEGF-vascular endothelial growth factor, CSF-cerebrospinal fluid. 
 
Discussion 
Key Findings 	  
Plasma levels of IL-6, IL-8 and IL-15 were greater in aSAH when compared to 
controls within the first seven days of ictus.  CSF levels of all mediators 
except for IL-1α were higher than controls throughout the course of aSAH.  
For aSAH patients, no specific trends could be identified in the plasma during 
the course of aSAH.  For CSF, however, IL-1α, IL-1β, IL-4, IL-6, IL-8 and 
TNF-α increased in the early stages following aSAH (between days 3 and 5).  
Although patients with DIND did show a trend for lower plasma mediator 
levels of IL-1β, IL-10, IL-15 and TNF-α, this reached statistical significance at 
day 3 for IL-10 only.  Conversely, CSF levels of IL-1β, IL-4, IL-17, TNF-α and 
VEGF tended to be higher in patients with DIND at all time points although 
this reached significant values on day 5 for VEGF only.  Although no specific 
trends in plasma could be identified on the day of commencement of DIND, 
CSF levels were significantly higher than non-DIND patients for most 
mediators. 
Systemic and CNS inflammatory response following aSAH 	  
Plasma levels of IL-6 and IL-8 were higher in aSAH patients than in controls.  
This supports the role of both mediators being produced systemically and 
promoting an acute phase response219.  A more substantial finding however is 
that CSF levels of IL-6 and IL-8 have been shown to be raised and compared 
to non-aSAH controls, shown to be anywhere between 1.5-10000-fold 
higher219,299-302,305,307.  This is in agreement with the current study that 
demonstrated 680-fold and 50-fold higher CSF IL-6 and IL-8 levels 
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respectively in aSAH patients than when compared with non-aSAH controls.  
Absolute concentrations and the large variation and spread of the data are 
also similar219,299,305.  As noted in the current study, CSF IL-6 and IL-8 levels 
have been shown to increase and peak around day 5 post ictus, with a 
subsequent decline to lower, albeit pathological levels by day 14219,303,305.  
The relatively slower peak at day 5, supports the known mechanisms of action 
for IL-6.  In the CNS following ischaemia, early release of IL-1β and TNF-α 
results in a second and more persistent inflammatory response mediated by 
IL-6 and IL-8.  β-adrenergic stimulation may be involved in the production of 
IL-6 in this setting346.  Both IL-6 and IL-8 are important in leukocyte 
aggregation and adhesion which is thought to play a role in the periadventitial 
space around the microvasculature surrounded by the spilled blood in the 
subarachnoid space204.   
 
As has been seen in the present study, the concentration of IL-1β in the CSF 
soon after aSAH was shown to be greater than in non-aSAH controls 302.  It is 
unclear from the literature what the absolute values are following aSAH, with 
a range of 2-80 pg/ml being reported347.  The time-course demonstrates a 
peak at day 5 post ictus followed by a steady decline to lower levels by day 10 
post ictus, although this time-course has not been consistently 
demonstrated299,305.  In the current study, there is a similar time-course 
observed with absolute values lying within those reported in the literature.  IL-
1α increased in the CSF early after aSAH but this difference was not 
significant.  Levels were never significantly different from controls, with a trend 
for lower plasma values in aSAH patients.  IL-1α was one of only two 
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investigated mediators that was found more abundantly in the plasma than in 
CSF.  This lack of association with aSAH and DIND has some support from 
another study that could not detect IL-1α in the CSF following aSAH301. 
 
Levels of CSF TNF-α in control subjects in the current study are 40-fold higher 
than that described in the literature299.  This may be explained by the different 
types of controls utilised.  In the literature, control subjects often constitute 
patients undergoing lumbar puncture for suspected aSAH or meningitis 
without a subsequent positive diagnosis.  In the current study, control subjects 
are patients undergoing an elective joint replacement (knee or hip) requiring 
spinal anaesthesia.  These patients did not present with any acute pathology 
and were screened for any systemic inflammatory response.  Patients with 
inflammatory arthropathy were not included.  TNF-α has been shown to be 5-
30 fold higher in the CSF of aSAH when compared to control, peaking at 
around day 7299,302,304.  This increase may be related to those with an 
unfavourable outcome304.  In the current study, TNF-α peaked slightly earlier 
on day 5, with absolute values considerably higher than those previously 
documented299.  The global increase in TNF-α in both controls and CSF may 
suggest a fundamental assay difference for this mediator even though 
multiplex analysis were used for both studies. 
 
MCP-1 has been shown to be elevated in the plasma and CSF following 
aSAH in comparison with non-aSAH controls and this difference noted to be 
more marked in the CSF262,300,307.  In the current study, this effect was noted 
in the CSF only.  As is seen in the present study, control values were higher in 
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plasma than in CSF262.  The level of MCP-1 was shown to be proportional to 
the grade of the patient and the weaker response in plasma was thought to 
represent a weaker systemic inflammatory response in good grade patients.  
The lack of difference between plasma levels in aSAH patients and controls in 
the current study may be a result of the good grade cohort being investigated. 
 
Systemic and CNS inflammatory response associated with DIND 	  	  
CSF IL-6 and IL-8 levels have been shown to be higher in patients with 
DIND219,299,300,302,305,306,311 and associated with a poor outcome at three 
months following haemorrhage310.  This increase was as early as day 1 post 
ictus and sustained throughout the course of aSAH.  CSF IL-6 levels were 
also higher in patients with increased flow velocities on TCD examination299.  
This cohort exhibited a greater peak of IL-6 concentration.  CSF IL-6 levels 
were elevated 0-3 days post-haemorrhage in those of poor clinical grade with 
subsequent DIND306.  According to binary logistic regression, there was a 
statistically significant effect on days 4 and 5 for the prediction of DIND and 
day 7 for cerebral ischaemia related to DIND219.  A cut-off point of 2000 pg/ml 
on day 4 came with an eleven-fold relative risk of DIND.  An alternative cut-off 
point has been described as 400 pg/ml on day 3311.  This has not been 
demonstrated in the current study.  Although median levels were higher in 
DIND patients at day 3, this was not a significant or sustained effect.  This 
was also noted for CSF IL-6 levels taken at the time of commencement of 
DIND.  Half of patients with DIND and half without DIND had a CSF IL-6 level 
of >2000 pg/ml in the current study.  A possible explanation for this is the 
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smaller number in the current study unable to confirm the significance of this 
change at day 3.  It is interesting to note that in the study by Schoch and 
colleagues, no association was found between DIND/delayed cerebral 
ischaemia and WFNS grade, Fisher grade and length of stay in the critical 
care unit.  This may highlight fundamental differences between this study and 
the current study in relation to the aSAH cohort and diagnostic criteria for 
DIND.  It was noted in their study that there was a disproportionate weighting 
towards poor grade patients; the opposite effect was noted in the current 
study, which was limited to good grade aSAH patients only.   
 
Blockade of IL-8 effects has been shown to be beneficial following transient 
ischaemia but not permanent ischaemia235,348.  This would suggest that IL-8 
(or a downstream factor) confers damage during the re-perfusion phase of 
ischaemia.  Leukocyte accumulation may have an important role in this.  This 
is especially relevant for patients with new onset DIND who have not yet 
established an infarct and are likely to exhibit focal compromises to cerebral 
blood flow that are initially dynamic and subject to fluctuation at the 
microvascular level.    
 
CSF IL-1β levels have been shown to be higher in patients with increased 
flow velocities on TCD examination, with a greater peak concentration at day 
5 post ictus299.   Although a very similar trend was seen in the current study, 
the difference was not statistically significant for patients with DIND.  This is 
likely to be due to the smaller numbers in the current study and the inherent 
differences between angiographic vasospasm and DIND.  A higher trend in 
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DIND was noted at all time-points, particularly at day 3.  This is supported by 
the observation that CSF IL-1β taken at admission was three-fold higher in 
those with subsequent DIND and subsequent samples taken between days 8 
and 15 were higher in those with DIND302,306.  Given the diverse set of 
circumstances that can result in IL-1α and β release and the diversity of their 
subsequent response, it is difficult to predict exactly what role they have in 
aSAH and the subsequent clinical course.  There is a lack of consensus in the 
literature as to the correlation of IL-1β levels and the occurrence of DIND 
(table 8).  This is likely to be due to the temporal expression profile of these 
molecules and the potentially conflicting pro- and anti-inflammatory effects 
they may have depending on the relative concentration and contribution of 
other existing cytokines.  This of course needs to be interpreted in the context 
of anatomical location; between the systemic compartment and the CNS and 
also temporal differences within the CNS.  
 
CSF TNF-α was higher in patients with increased flow velocities on TCD 
examination, peaking at day 7 and subsiding at a slower rate in this subset of 
patients299.  CSF TNF-α taken at admission was double in those with 
subsequent DIND302.  These findings are reflected in the current study that 
has demonstrated a higher trend in DIND patients at all time-points and a 
peak at day 5 that is sustained until day 9 in those with DIND.    
 
VEGF was the only mediator in the current study to be significantly higher in 
patients with DIND (only on day 5).  Although it has been implicated in BBB 
disorders and is upregulated following experimental TBI and hypoxia278,279, 
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this is the first demonstration in humans of an association with DIND.  It is 
difficult to interpret this finding given that it was elevated in the CSF in all 
aSAH patients when compared with controls and tended to be even higher in 
those with DIND at all measured time-points.  It is not possible to determine 
whether this response is a cause or consequence of ischaemia or simply 
epiphenomena.  A possible mechanism of how VEGF can cause or contribute 
to DIND lies in its ability to disrupt the BBB.  Cerebral oedema (even in a 
focal/microvascular capacity) may be the starting point which compromises 
cerebral blood flow and triggers the secondary insults resulting in DIND.  
Alternatively, DIND is triggered by some another unknown mechanism and 
the subsequent rise of VEGF triggers/worsens cerebral oedema and starts the 
cycle of secondary brain injury.  Src-family tyrosine kinase and MAPK are 
important pathways associated with VEGF281,282  
 
CSF and not plasma levels of MCP-1 have been shown to correlate with 
angiographic vasospasm in aSAH patients262.  In a subgroup of good grade 
patients with and without vasospasm, this correlation was no longer present.  
Although DIND and not angiographic vasospasm was investigated in the 
current study, this association was not seen.  This may in part be explained by 
the good grade cohort in this study and by the different pathological 
processes that are likely to be taking place in angiographic vasospasm and 
DIND. 
 
Regression analysis in the current study did not highlight any mediators that 
were independent predictors of early and long-term outcome in this cohort. 
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Compartmentalisation of inflammation following aSAH 	  	  
The overall consensus from the literature is that the mediators found 
abundantly in the CSF following aSAH are not as prominent in the plasma, 
suggesting intra-thecal production299,305,308.  There has been some evidence 
implicating raised IL-6 values in the peripheral and central venous system with 
DIND349.  In agreement with previous studies IL-1β, IL-6 and IL-8 were lower 
in the plasma in the current study compared to simultaneous CSF samples 
although in the case of IL-6 and IL-8, plasma levels were still significantly 
higher than non-aSAH controls299,303,305,308.  It is not possible to determine 
whether this represents two separate sites of mediator production in a 
combined systemic/CNS inflammatory cascade, or production at one of these 
sites with subsequent migration.  The existence of SIRS in aSAH would 
support the former whereas the overwhelmingly larger mediator 
concentrations seen in the CSF would support the latter.  In the case of IL-1β, 
another study has shown this to be completely undetected in the plasma305.  
TNF-α was significantly higher in the CSF in the current study and although 
this does have some support308, others have shown no difference between 
the two concentrations299. 
 
Mediator concentrations within the ECF are also uncertain following aSAH.  
Although studied in a mixed cohort of aSAH, ischaemic stroke and TBI 
patients, microdialysis catheters placed during the first 72 hours following 
haemorrhage demonstrated very high IL-1β concentrations (approximately 20 
pg/ml) in the first 6 hours, followed by a steady decline to less than 4 pg/ml309.  
These findings closely precede the CSF findings in the current study (where 
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the first measurement is at 72 hours) and other CSF findings299.  ECF IL-6 
levels did also rise but in a slightly delayed fashion when compared with IL-1β 
(6-12 hours)309.  Absolute values are also comparable with CSF299.  This 
would suggest that IL-6 levels do fluctuate as early as 12 hours post-ictus: 
activity that would have been missed in the current study due to the first 
sample being taken at 72 hours.  In a study of aSAH exclusively, IL-6 was 
elevated in all three compartments in all patients312.  This was followed by a 
systemic inflammatory response (as measured by CRP) between days 7-9 
only in those with DIND.  IL-6 was higher in those with symptomatic DIND 
particularly in the CSF and ECF (no associated with plasma levels).   
 
ECF IL-10 values were not subject to any significant fluctuations within the 
first 72 hours following haemorrhage, with a median concentration of 10-12 
pg/ml309.  This is supported by the current study demonstrating median 
concentrations in the CSF between 9-12 pg/ml betweens days 3-9.  Plasma 
levels of IL-10 were also not subject to fluctuation and were found to be 
approximately one-third of CSF levels in magnitude. 
 
The chemokine IL-8 demonstrated a peak value (approximately 4000 pg/ml) 
on initial assessment in the ECF at 6 hours post haemorrhage and underwent 
a steady decline to 500 pg/ml at 72 hours350.  The 72 hour levels reflect those 
found in the current study within the CSF at that time.  Plasma levels were 
found to be approximately 10-fold less than CSF levels and not subject to 
these fluctuations.  This would support the early rise and fall of IL-8 within the 
CNS.   
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Whereas the median concentration of VEGF in the ECF following aSAH and 
other intracranial pathologies was relatively constant for the first 36 hours, our 
results would suggest that absolute values were approximately four-fold 
greater in the CSF and plasma350.  
Limitations of the study 	  	  
Single samples taken every 48 hours only capture a limited picture of the true 
inflammatory profile.  The changes taking place in the 7-10 days following 
aSAH are likely to impact heavily on mediator levels regardless of the 
presence or absence of DIND or the initial severity of the haemorrhage.  In 
order to assess this more thoroughly, more frequent samples need to be 
taken (every 4-6 hours) in order to construct a better impression of molecular 
events. 
 
Although cytokines are measured together using Multiplex technology, the 
analysis in the current study has kept those mediators separate.  Cytokine 
profiling is a complex process and cytokines are likely to modulate and 
potentiate each other.  Each cytokine is likely to behave in a completely 
different way depending on its concentration, site of action and the temporal 
expression of other mediators.  Improved data modelling is required to aid 
interpretation of this complex dataset (particularly if more frequent samples 
are taken).  Using the Games-Howell test for post-hoc analysis helps adjust p-
values for multiple comparisons and is particularly useful for unequal group 
sizes with unequal variances and for small sample sizes per cell.  It is based 
 146	  
on Welch’s correction to degree of freedom with the t-test and uses the 
studentized range statistic. 
 
The current study relied upon CSF obtained from a lumbar drain.  This device 
is likely to stimulate its own local inflammatory reaction with time.  An ideal 
control for this (not available in the current study) would be CSF obtained from 
a single lumbar puncture at days 3, 5 , 7 and 9 in a patient randomised to the 
control arm of the lumbar drain trial (and so without a lumbar drain). 
Summary 
 
Although definite conclusions cannot be drawn from the current study 
regarding the role of inflammation following aSAH, it is clear that an 
inflammatory response is initiated following the haemorrhage, likely to peak at 
day 5-7 post ictus and localised within the CNS relative to the systemic 
compartment.  VEGF may have a particular association with incipient DIND 
but any further conclusions about the chronology of events are not possible 
from the current study.  This mediator should be subject to further 
investigation in a larger study extracting it from the ECF, CSF and plasma 
simultaneously.
Final conclusions and 
future direction 
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The prevalence of DIND following aSAH has been reduced with the use of 
lumbar drainage of CSF post ictus.  This is likely to be due to a combination of 
blood clearance and control of ICP although the former is a more likely 
explanation for this.  Patient recovery was quicker with lumbar drains but long-
term outcome was no different.  Despite this, there is reasonable support from 
this trial for the routine use of lumbar drains in all good grade aSAH patients.  
Similar results from a second trial (ideally incorporating poor grade aSAH 
patients) would give strong support for the routine use of lumbar drains.  
Larger patient numbers and better outcome measures would need to be 
incorporated in order to detect any possible subtle differences in long-term 
outcome. 
 
Cytokines appear to be important mediators involved in DIND.  Whether their 
effects are the cause or consequence of ischaemia or a response that is seen 
concurrently in patients with DIND but not directly related to it, is unclear.  In 
fact, all the inflammatory mediators that did show non-significant trends 
following aSAH and associations with DIND were not conclusively shown to 
be causative mediators.  VEGF is highlighted from the current study as a new 
target for a future investigation.  This should extend to include sampling the 
ECF with microdialysis technology and involve multiple sampling throughout a 
24-hour period in order to ascertain if there are frequent fluctuations in 
mediator levels.  Snap-shots every 24-48 hours will not suffice.  Advanced 
modelling techniques will need to be applied in order to interpret such large 
amounts of data correctly and accurate correlation to clinical parameters 
needs to be made.  Single mediator analyses are unlikely to yield meaningful 
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results since cytokines are likely to function as dynamic signalling networks.  
The same mediators may simultaneously be able to stimulate both a pro-
inflammatory and anti-inflammatory state depending on its concentration and 
interaction with other mediators.  In the CNS, these conflicting responses may 
be occurring simultaneously in different parts of the brain anatomically and 
physiologically in different compartments.  In fact, the terms pro-inflammatory 
and anti-inflammatory are likely to be over-simplifications.  As opposed to 
focusing on single mediators, multiplex technology allows multiple mediators 
to be measure in duplicate or triplicate.  This could potentially allow mediator 
results to be combined in order to help elucidate what the overall inflammatory 
status was at the time and place of sampling.  This may be a more 
constructive way of interpreting this complex data. 
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Statement of individual 
contribution 	  
Yahia Al-Tamimi (YA) was the priniciple investigator and conductor of this 
research.  Deepti Bhargava (DB) acted as a research assistant in the conduct 
of the trial during the period 2008-2010.  The diagnosis of DIND was made 
prospectively by the multidisciplinary team caring for the patient: this included 
a vascular neurosurgeon (of which there are four), several neurointensivists 
and a neuroradiologist.  The two investigators involved in the management of 
the trial (YA and DB) did not make this diagnosis.  Neurological examination 
in this setting was performed by a number of clinicians completely 
independent of the trial and repeated several times daily (in addition to 
standard hourly nursing observations).  Only after an established diagnosis 
did the investigators make a prospective independent assessment of 
neurology to confirm this diagnosis (there were no instances of disagreement 
at this stage).  Retrospective verification at the end of the trial by the 
investigators was performed with prospectively collected clinical data (without 
any reference to treatment allocation), blood results and radiological images.  
No disagreements did occur between this retrospective assessment and the 
prospective assessments.  The Modified Rankin Score at day 10 was 
performed by YA/DB following a short discussion with the physiotherapist 
involved with the care of a particular patient.  This was subsequently verified 
by the investigators (there were no instances of disagreement between these 
two assessments).  For those few patients discharged before day 10, an 
assessment of the MRS was performed over the phone in a similar fashion to 
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the six-month MRS. The six-month MRS was obtained by YA and DB.  In 
order to minimise bias, the investigator was blinded to treatment allocation 
and where possible, the task was performed by the investigator who was not 
directly involved in recruiting patients.   
 
The data monitoring committee consisted of two vascular neurosurgeons not 
involved with the trial (Mr A Tyagi and Mr N Phillips, Leeds Teaching Hospital) 
and the trial statistician (Mr R Feltbower).  The trial statistician performed the 
interim analysis.  The aims of the interim analyses at 40 patients and 100 
patients were to highlight any safety issues and to demonstrate obvious 
benefit/detriment of trial intervention respectively.  
 
The second part of this study (multiplex analysis) was performed by YA and 
Dr Uma Ekbote.  YA collected all the samples and acted a laboratory 
assistant to Dr Ekbote who led the analysis. 
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Appendix One 	  
Lumbar drainage of cerebrospinal fluid 
following aneurysmal subarachnoid 
haemorrhage: A prospective, randomised 
and controlled trial (LUMAS)  
 
 
Trial Protocol 
 
Chief Investigator: 
Mr Yahia Al-Tamimi 
Senior Investigator 
Mr Stuart Ross 
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Introduction 
 
Aneurysmal subarachnoid haemorrhage affects between six and eight per 
100,000 population per year.  Despite modern intervention the mortality and 
morbidity rate remains high both from the initial haemorrhage and from the 
associated complications of subarachnoid haemorrhage.  The two major 
neurological complications (excluding re-haemorrhage) seen in patients with 
subarachnoid haemorrhage are cerebral vasospasm and hydrocephalus. 
 
Cerebral Vasospasm 
 
Cerebral vasospasm is characterised by delayed neurological deficit and/or 
impairment of the level of consciousness occurring after the third or fourth day 
post-haemorrhage.  The period in which cerebral vasospasm may occur 
extends from the third to the twenty-first day post-bleed, but is most 
commonly seen between days three and fourteen.  Although seen in up to 
70% of angiograms, clinically apparent cerebral vasospasm occurs in around 
30% of patients in large series.  Of these, as many as 50% will develop a 
permanent cerebral infarction with 15-20% of patients suffering severe 
disability or death.  The cause of cerebral vasospasm is unknown, but many 
workers believe that the presence of a cerebrospinal fluid (CSF borne 
spasmodic agent derived from the breakdown products of subarachnoid blood 
is responsible).  Several candidate agents have been suggested including 
catecholamines, serotonin, prostaglandins and oxyhaemoglobin released 
during red-cell lysis. 
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A number of factors predicting the likelihood of developing cerebral 
vasospasm have been identified.  Of these the volume of blood seen on initial 
CT scan has the greatest predictive value. 
 
The diagnosis of cerebral vasospasm is made by clinical evaluation in 
conjunction with supportive investigations including CT scan and, where 
available, trans-cranial Doppler ultrasonography of the large intracranial 
vessels.  However the investigation of choice to demonstrate vasospasm is 
cerebral angiography.    
 
Early recognition of incipient vasospasm enables aggressive treatment to be 
given which consists of hypervolaemia, hypertension and haemodilution 
(HHH).  This three-pronged approach is aimed at providing adequate cerebral 
perfusion.  Supplementary oxygen and control of sodium balance (patients 
with cerebral vasospasm are prone to centrally-mediated natriuresis) are 
important adjuncts to HHH therapy.   
 
A recent retrospective study has suggested that continuous drainage of CSF 
via a lumbar drain has a significant impact on patients with cerebral 
vasospasm, reducing the incidence and severity of the condition and 
improving overall outcome.  The suggested mechanism by which this benefit 
is achieved is removal of the presumed CSF borne spasmogen.  This 
research group compared the practice of two vascular neurosurgeons during 
the period of 1994 and 2003.  One surgeon routinely placed an intra-operative 
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lumbar drain during clipping or endovascular coiling of an aneurysm (unless 
contraindicated), whilst the second surgeon did not.  Data was collected on 
167 patients.  
 
All patients received standardised care and were placed into two groups, 
those that had lumbar drainage (number of patients 81) and those that did not 
(control group, number of patients 86).  Outcome measures included the 
development of clinically evident vasospasm, the need for endovascular 
interventions (including angioplasty and/or intra-arterial papaverine) and the 
development of vasospasm-related infarction.  Results were in favour of 
lumbar drainage.  There was a statistically significant reduction in the 
incidence of clinically symptomatic vasospasm (from 51% to 17%), need for 
endovascular therapy (from 45% to 17%) and vasospasm-related infarction 
(from 27% to 7%).  There was also a statistically significant improvement in 
disposition at discharge, length of in-patient stay and Glasgow outcome 
scores.   
 
Although a robust retrospective study, there were certain limitations.  The 
study had a degree of selection bias with a tendency of higher Fisher grades 
(appendix 1.3) not to have lumbar drainage.  Logistic regression analysis and 
subgroup analyses showed that following correction for this bias, results were 
still in favour of lumbar drainage.  Other limitations of the study include the 
long period in which patients presented to the department (9 years) and the 
inherent limitations to retrospectively analysing case notes.  Other features 
that could be addressed in a future study include quantification of the amount 
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of CSF drainage (including the amount intraoperative drainage) and the use of 
lamina terminalis fenestration during the operation and the implications this 
would have in the outcome measures.  These factors have not been 
adequately addressed in this study. 
 
Study Aims 
 
The aim of this study is to determine whether continuous lumbar drainage of 
CSF reduces the incidence and severity of clinical vasospasm and leads to 
improved long-term outcome.  Lumbar drainage of CSF is a cheap, safe 
procedure performed under local anaesthesia and is routinely used in patients 
undergoing surgery for intracranial aneurysms to facilitate surgery.  There are 
a number of contraindications to lumbar drain insertion, which are outlined in 
the exclusion criteria for this study. 
 
Study Design and Methodology 
 
This study is a prospective, randomised, case-controlled study in which 
patients will receive standard therapy or standard therapy plus lumbar 
drainage following initial CT scan.   
 
Written informed consent will be sought prior to recruitment into the study.  
Written assent from the patient’s relatives will be sought in those cases where 
confusion prevents written informed consent being obtained from the patient. 
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Patients with CT evident subarachnoid blood corresponding to Fisher Grades 
2, 3 and 4 (appendix 1.3) will be randomised to standard therapy or standard 
therapy with the addition of continuous lumbar drainage of CSF at 5-10 mL 
per hour until the CSF shows no evidence of xanthochromia or day 10 post-
insertion.  Patients will be entered into the study as soon as possible following 
haemorrhage, but not after 96 hours post-haemorrhage day (i.e. prior to the 
onset of vasospasm).  
 
Patients may withdraw from the study at any time and will continue with 
routine management. 
 
Should the lumbar drain fall out prematurely the patient will be asked whether 
they wish to continue in the study and, if so, the lumbar drain will be 
reinserted and management will continue as before.   
 
Patients showing signs of lumbar drain infection will have the drain removed, 
a sample of CSF and the drain tip sent to the microbiology laboratory and 
appropriate antibiotic therapy instituted.  Appendix one demonstrates the flow 
diagram for patient recruitment. 
 
Inclusion / Exclusion Criteria 
 
Inclusion criteria 
Aneurysmal subarachnoid haemorrhage. 
Recruitment prior to 96 hours post-haemorrhage. 
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Written informed consent or relative assent given. 
WFNS grade 1-3 (Appendix 1.2). 
Fisher grade 2, 3 and 4 (without space occupying haematoma) on initial CT 
scan (Appendix 1.3). 
No significant intraventricular haemorrhage, space occupying haematoma or 
other contra-indication to lumbar puncture. 
 
Exclusion criteria  
Non-aneurysmal subarachnoid haemorrhage. 
Delayed presentation / recruitment (after 96 hours post-haemorrhage) 
Written informed consent or relative assent denied or unobtainable. 
WFNS grade 4 or 5 (Appendix 1.2). 
Fisher grade 1 on initial CT scan (Appendix 1.3). 
Intraventricular haematoma obstructing ventricular outflow. 
Intracranial haematoma with mass effect. 
Bleeding diathesis.  
 
Outcome Measures 
Primary Outcome Measure 
Development of clinical vasospasm (new delayed neurological deficit and / or 
impairment of consciousness without other cause).  This is defined as a drop 
of one motor point or two eye/verbral points of the Glasgow Coma Score 
and/or a new focal neurological deficit, seen at least 96 hours post 
haemorrhage. 
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Secondary Outcome Measures 
Modified Rankin score at day 10 and six months post-discharge. 
Development of completed stroke clinically and radiologically (when 
computerised tomography is performed as part of routine clinical care). 
CSF Infection. 
Prevalence of cerebrospinal fluid shunting. 
 
Special Note on the Trial Protocol 
 
If a patient has presented greater than four days following the initial 
haemorrhage, any neurological deficit present may be a delayed ischaemic 
neurological deficit and thus must be excluded from the trial.  Should the 
lumbar drain fall out prematurely the patient will be asked whether they wish 
to continue in the study and, if so, the lumbar drain will be re-inserted and 
management will continue as before.  Patients showing signs of lumbar drain 
infection will have the drain removed, a sample of CSF and the drain tip sent 
to the microbiology laboratory and appropriate antibiotic therapy instituted. 
 
In those patients that present with or develop raised intracranial pressure 
secondary to hydrocephalus, if indicated, an external ventricular drain would 
be inserted regardless of trial status.  If subsequently randomised to the study 
arm of the trial, a lumbar drain would be inserted and cerebrospinal fluid 
drainage gradually weaned off the external ventricular drain into the lumbar 
drain.  The external ventricular drain can subsequently be removed.  Those 
patients with an external ventricular drain that are subsequently randomised 
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to the control arm of the trial shall be analysed as a separate group of 
controls.   
 
Those patients that develop raised cerebrospinal fluid pressure whilst a 
lumbar drain is in situ would have their drain readjusted to be pressure 
dependant and not volume dependant (i.e. the pursuit of cerebrospinal fluid 
drainage of 5-10 ml/hour would no longer be appropriate and the drain would 
be sent to maintain normal ventricular pressure (15 cm/water above 
zygoma)).  
 
Although primarily a clinical study with clinical outcome measures, 
transcranial Doppler may be used to aid diagnosis of radiological vasospasm.  
This will act as a guide to therapy only.  Increase flow velocity is not a pre-
requisite for the diagnosis of delayed ischaemic neurological deficit. 
 
Statistical Analysis 
 
The neurosurgical unit at Leeds General Infirmary treated 313 patients with 
acute subarachnoid haemorrhage in the three years 1997-2000.  Of these 243 
patients would have been suitable for this study on the basis of their 
admission clinical status. 
 
The power calculation based on the hypothesis that lumbar drainage will 
result in a twenty percent reduction in the incidence of vasospasm requires 
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the recruitment of 105 patients to each arm of the study to achieve 85% 
power (appendix 1.4). 
 
Conclusion 
 
Aneurysmal subarachnoid haemorrhage remains an important cause of 
mortality and morbidity in neurosurgical practice.  Cerebral infarction 
secondary to the onset of cerebral vasospasm is the main cause of mortality 
and morbidity in those patients who survive the initial haemorrhage.  Cerebral 
vasospasm is thought to result from CSF borne blood breakdown products.  
Recent retrospective studies have suggested that continuous lumbar drainage 
of CSF reduces the incidence and severity of cerebral vasospasm and results 
in improved outcome.  No prospective randomised study has been performed 
to address this question. 
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Appendix 1.1-Flow diagram of patient recruitment 
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Appendix 1.2 – World Federation of Neurosurgeons Grading of 
Subarachnoid Haemorrhage 
 
 
WFNS Grade Glasgow Coma Score Motor Deficit 
 
1 
 
15 
 
None 
2 13-14 None 
3 13-14 Present 
4 7-12 None / Present 
5 3-6 None / Present 
 
 
Appendix 1.3 – Fisher classification of Subarachnoid Haemorrhage 
 
Fisher 
Grade 
Description of CT appearance 
1 No blood detected 
2 Diffuse deposition of subarachnoid blood, no clots, no layers of 
blood greater than 1mm 
3 Localised clots and/or vertical layers of blood 1mm or greater in 
thickness 
4 Diffuse or no subarachnoid blood, but intracerebral or 
intraventricular clots are present 
3+4 Both dense subarachnoid blood and 
intracerebral/intraventricular haemorrhages of 5 ml or more 
(greater than 2cm) 
 
Appendix 1.4-Power calculation for the trial 
 
 
Incidence of 
DIND 
30 % 25 % 20 % 15 % 10 % 
Absolute 
Change 
-10 % -15 % -20 % -25% -30% 
Power 80 % 375 165 90 60 40 
85 % 430 190 105 65 45 
90 % 500 215 120 73 50 
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Appendix 1.5-Modified Rankin Score 
 
Score Description 
0 No symptoms at all 
1 No significant disability despite symptoms; able to 
carry out all usual duties activities 
2 Slight disability; unable to carry out all previous 
activities, but able to look after own affairs without 
assistance  
3 Moderate disability; requiring some help, but able to 
walk without assistance 
4 Moderately severe disability; unable to walk without 
assistance and unable to attend to own bodily needs 
without assistance 
5 Severe disability; bedridden, incontinent and 
requiring constant nursing care and attention 
6 Dead 
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Consent Form 
 
 
Spinal Fluid Drainage in Subarachnoid Bleed 
 
 
Patient Identification number   [                     ] 
 
I have read the attached Patient Information Sheet      
I have had the opportunity to ask questions and have received answers to my satisfaction 
I understand that I may not gain any personal benefit from participation in this study   
The additional risk to me above that covered in the consent for my operation has been 
explained to my satisfaction          
I understand that all information relating to my case will be stored within a secure database 
and that if presented or published all personal details will be withheld    
I understand that I may withdraw my consent at any time without affecting my routine 
treatment or legal rights          
I understand that that cerebrospinal fluid and venous blood that is removed as part of this 
study may be stored anonymously for further biochemical analysis and disposed of 
accordingly    
 
Signed        Date 
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I confirm that I have explained the purpose of the study and am satisfied that the patient has 
an adequate understanding of the study 
 
 
Signed        Date 
The Leeds Teaching Hospitals NHS Trust 
 
Patient Information Sheet 
 
Spinal Fluid Drainage in Subarachnoid Bleed 
 
You are being invited to take part in a RESEARCH STUDY.  Before you decide, it is important 
for you to understand why the research is being done and what it will involve.  Please take the 
time to read the following information carefully and discuss it with friends, relatives and your 
GP if you wish.  Ask us if there is anything that is not clear, or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
Background and Purpose of the Study 
 
We are trying to find out whether drainage of spinal fluid results in better outcome for patients 
with subarachnoid haemorrhage.  There is evidence to show from a previous study that 
inserting a spinal drain following subarachnoid haemorrhage has reduced the complication 
rate following this type of haemorrhage.  The main complication is a process called 
vasospasm which is serious and poorly understood.  It is associated with neurological 
deterioration and disability.  There is evidence that spinal drainage may reduce the chance of 
this occurring.  However, this has yet to be proven with a detailed and effective study like this 
one we are performing. 
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Why have I been chosen? 
 
We hope to include all suitable patients with subarachnoid haemorrhage in the Neurosurgery 
Department in Leeds. 
 
Do I have to take part? 
 
Participation is entirely voluntary, you may withdraw from the study at any time without having 
to give reasons and your routine hospital care and legal rights will not be affected.  If you 
decide to take part you will be given this information sheet to keep and will be asked to sign a 
consent form. 
 
What will happen to me if I take part? 
 
If you decide to take part, we will place you into one of two groups (called group 1 or group 2).  
If placed in group 1, you will be given normal therapy and treatment.  Normal treatment 
consists of keeping you on a special ward where there are many nurses available to look after 
you.  We will place a small plastic tube into your vein (called a cannula) in order to give you 
fluid therapy directly into your blood.  This will ensure you receive adequate amounts of water 
and salt.  We will take regular blood tests (possibly daily) to keep a close eye on salt levels in 
your blood.  You will be given tablets every 4 hours to help your brain cope with this 
haemorrhage.  We may feel the need to place further small tubes (similar to the cannula in 
your vein) in your neck and wrist to help monitor you closely.   
 
If we decided to place you in group 2, you will receive all the standard therapy described 
above in addition to a spinal drainage tube which we place in your lower back.  This will be 
attached to a bag to collect spinal fluid.  This may stay in your back for 1-2 weeks.  This 
procedure is carried out under local anaesthetic and although application of this local 
anaesthetic may be slightly uncomfortable, the procedure should be painless.  You will be 
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asked to turn to your side with your legs curled up.  Your lower back will be cleaned with 
disinfectant and a small needle will be used to inject some local anaesthetic.  The procedure 
should take no longer than twenty to thirty minutes.  Once the drain is inserted, you will be 
allowed to move as your condition allows. 
 
The way we decide which group you will be placed in is on a random basis.  This is like 
tossing a coin to decide the group.  If it lands on heads, you will be placed in group 1 and if it 
lands on tails, you will be placed in group 2.  Another way to understand this is to think of a 
roulette wheel.  If the ball lands on red, you are put in group 1 and if the ball lands on black, 
you are put in group 2.  This means there is an equal chance that you will be placed in either 
group 1 or group 2.  This method ensures that the study is scientifically accurate.   
 
Are there any benefits from taking part? 
 
There may be no benefit to you from participation in this study.   We are investigating whether 
or not spinal drainage does improve the patient’s outcome following subarachnoid 
haemorrhage. 
 
Are there any risks? 
 
There is a very small risk of infection in the spinal fluid (we estimate this to be less than one 
percent).  Although this complication is not often seen, we treat it very seriously.  We will 
continually assess for signs of infection including inspection of the drain site and sending 
spinal fluid samples to the laboratory to look for infection.  We collect this from the draining 
bag and so it will not require any further needles or injections.  If there is any sign of infection 
we will remove the drain and treat appropriately (with antibiotics if necessary).   
 
Will my taking part in this study be kept confidential? 
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All information collected in the study is confidential.  You will not be able to be identified at 
any time including during presentation or publication of the study results. 
 
What will happen to the results of the study? 
 
We hope to publish the results in a medical journal.  You will not be able to be identified from 
published results. 
Who is organizing and funding the research? 
 
The Neurosurgical Department at Leeds General Infirmary. 
Who has reviewed the study? 
 
The study has been reviewed by the Leeds (West) Research Ethics 
Committee. 
 
Contact for further information 
 
Mr Yahia Al-Tamimi (Lead Investigator) 
  
Neurosurgery Dept, Leeds General Infirmary 
 
Mr Stuart Ross (Consultant Neurosurgeon) 
 
Neurosurgery Dept, Leeds General Infirmary 
 
 
 
Thank you for your participation 
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Date:        Number: 
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Assent Form 
Spinal Fluid Drainage in Subarachnoid Bleed 
 
 
Patient Identification number   [                     ] 
 
 
 
I have read the attached Relative Information Sheet       
I have had the opportunity to ask questions and have received answers to my satisfaction  
 
I understand that the patient (my relative) may not gain any personal benefit from participation  
in this study            
 
The additional risk to the patient above that covered in the consent for his/her operation has  
been explained to my satisfaction         
 
I understand that all information relating to the patient's case will be stored within a secure  
database and that if presented or published all personal details will be withheld    
 
I understand that I may withdraw my assent on behalf of the patient at any time without 
affecting  
the patient's routine treatment or legal rights        
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I understand that cerebrospinal fluid and venous blood that is removed from the patient as 
part of this study may be stored anonymously for further biochemical analysis and disposed of 
accordingly            
 
Signed        Date 
 
I confirm that I have explained the purpose of the study and am satisfied that the relative has 
an adequate understanding of the study and is able to give informed assent on behalf of the 
patient 
 
 
Signed        Date 
Relative Information Sheet 
The Leeds Teaching Hospitals NHS Trust 
 
 
 
Spinal Fluid Drainage in Subarachnoid Bleed 
 
 
Your relative (the patient) is being invited to take part in a RESEARCH STUDY.  In view of 
the patient's impaired ability to provide consent for this, you are being asked on their behalf to 
give permission for the patient to take part in this study.  Before you decide, it is important for 
you to understand why the research is being done and what it will involve.  Please take the 
time to read the following information carefully and discuss it with friends, relatives and the 
patient's GP if you wish.  Ask us if there is anything that is not clear, or if you would like more 
information.  Take time to decide whether or not you wish the patient to take part. 
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Thank you for reading this. 
 
Background and Purpose of the Study 
We are trying to find out whether drainage of spinal fluid results in better outcome for patients 
with subarachnoid haemorrhage.  There is evidence to show from a previous study that 
inserting a spinal drain following subarachnoid haemorrhage has reduced the complication 
rate following this type of haemorrhage.  The main complication is a process called 
vasospasm which is serious and poorly understood.  It is associated with neurological 
deterioration and disability.  There is evidence that spinal drainage may reduce the chance of 
this occurring.  However, this has yet to be proven with a detailed randomised study like this 
one we are performing. 
 
Why has the patient been chosen? 
 
We hope to include all suitable patients with subarachnoid haemorrhage in the Neurosurgery 
Department in Leeds. 
 
Does the patient have to take part? 
 
Participation is entirely voluntary, the patient may withdraw from the study at any time without 
having to give reasons and his/her routine hospital care and legal rights will not be affected.  If 
unable to make this decision, you can withdraw the patient from the study acting in his/her 
best interest.  If you decide to allow the patient to take part you will be given this information 
sheet to keep and will be asked to sign a consent form. 
 
What will happen to the patient if he/she takes part 
 
If the patient takes part, we will place him/her place into one of two groups (called group 1 or 
group 2).  If placed in group 1, he/she will be given normal therapy and treatment.  Normal 
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treatment consists of keeping the patient on a special ward where there are many nurses 
available to look after him/her.  We will place a small plastic tube into his/her vein (called a 
cannula) in order to give fluid therapy directly into the blood.  This will ensure that adequate 
amounts of water and salt are received.  We will take regular blood tests (possibly daily) to 
keep a close eye on salt levels in the blood.  The patient will be given tablets every 4 hours to 
help their brain cope with this haemorrhage.  We may feel the need to place further small 
tubes (similar to the cannula in the vein) in his/her neck and wrist to help monitor more 
closely.   
 
If we decided to place the patient in group 2, he/she will receive all the standard therapy 
described above in addition to a spinal drainage tube which we place in the lower back.  This 
will be attached to a bag to collect spinal fluid.  This may stay in the back for 1-2 weeks.  This 
procedure is carried out under local anaesthetic and although application of this local 
anaesthetic may be slightly uncomfortable, the procedure should be painless.  The patient will 
be turned to the side with their legs curled up.  The lower back will be cleaned with 
disinfectant and a small needle will be used to inject some local anaesthetic.  The procedure 
should take no longer than twenty to thirty minutes.  Once the drain is inserted, the patient will 
be allowed to move as their condition allows. 
 
The way we decide which group the patient will be placed in is on a random basis.  This is like 
tossing a coin to decide the group.  If it lands on heads, he/she will be placed in group 1 and if 
it lands on tails, he/she will be placed in group 2.  Another way to understand this is to think of 
a roulette wheel.  If the ball lands on red, the patient is put in group 1 and if the ball lands on 
black, he/she will be put in group 2.  This means there is an equal chance of being placed in 
either group 1 or group 2.  This method ensures that the study is scientifically accurate.   
 
Are there any benefits from taking part? 
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There may be no benefit to the patient from participation in this study.  We are investigating 
whether or not spinal drainage does improve the patient’s outcome following subarachnoid 
haemorrhage. 
 
Are there any risks? 
 
There is a very small risk of infection in the spinal fluid (we estimate this to be less than one 
percent).  Although this complication is not often seen, we treat it very seriously.  We will 
continually assess for signs of infection including inspection of the drain site and sending 
spinal fluid samples to the laboratory to look for infection.  We collect this from the draining 
bag and so it will not require any further needles or injections.  If there is any sign of infection 
we will remove the drain and treat appropriately (with antibiotics if necessary).   
 
Will the patient’s taking part in this study be kept confidential? 
 
All information collected in the study is confidential.  The patient will not be able to be 
identified at any time including during presentation or publication of the study results.  
 
What will happen to the results of the study? 
 
We hope to publish the results in a medical journal.  The patient will not be able to be 
identified from published results. 
 
Who is organizing and funding the research? 
 
The Neurosurgical Department at Leeds General Infirmary. 
 
Who has reviewed the study? 
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The study has been reviewed by the Leeds (West) Research Ethics Committee.  This 
committee has given their approval for this study. 
Contact for further information 
 
Mr Yahia Al-Tamimi (Lead Investigator) 
  
Neurosurgery Dept, Leeds General Infirmary 
  
Mr Stuart Ross (Consultant Neurosurgeon) 
 
Neurosurgery Dept, Leeds General Infirmary 
 
Thank you for your participation 
 
 
 
 
Date:        Number: 
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Registration  
Booklet	  for	  any	  
Subarachnoid	  
Haemorrhage	  patient	  
eligible	  to	  enter	  the	  
Lumbar	  Drain	  Trial	  	  Name	  of	  Patient……………………	  Hospital	  Number…………………..	  
	  
When	  to	  use	  this	  document:	  on	  admission	  of	  all	  SAH	  patient	  
regardless	  of	  inclusion	  into	  trial)	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Demographics	  
	  
Name	  	  	   	   	   	   	   	   Admission	  Date	  
Hospital	  Number	   	   	   	   	   DOB	  
Sex	   	   	   	   	   	   	   Address	  and	  Post	  code	  	  
Date	  of	  Bleed:	  
Date	  of	  Admission:	  
	  
Referring	  Hospital	  ………………………………………………………….	  
Admitting	  Ward:	   ITU	    	   	   HDU	    	   	   Ward	    	  	  
Diagnosis	  
	  
CT:	  blood	  in	  the	  following	  regions:	  Supracallosal	   	    	   	   	   	   Prepontine	   	    	  Interhemispheric	    	   	   	   	   Third	  Ventricle	    	  Convexity	   	    	   	   	   	   Fourth	  Ventricle	    	  Sylvian	   	    	   	   	   	   Lateral	  Ventricles	    	  Basal	  Cistern	   	    	  	   	   	   	   Posterior	  Fossa	    	  Perimesencephalic	    	   	   	   	   Other	  ……………………	  
	  
Is	  there	  ventriculomegaly?	   	   	   Yes	    	   	   No	    	  	  
Haematoma	  present?	   	   	   Yes	    	   	   No	    	  
If	  so,	  where?	  	   	   	   	   	   Sylvian	   	    	   	  	   	   	   	   	   	   	   Subfrontal	   	    	  	   	   	   	   	   	   	   Posterior	  Fossa	    	  	   	   	   	   	   	   	   Subdural	  haematoma	    	   mm	    	  	  
GCS	  when	  bleed:	   	   E	  	   	   	   M	  	   	   	   V	  	   	  
GCS	  at	  admission:	   	   E	  	   	   	   M	  	   	   	   V	  	   	  
WFNS	  grade:	  	   1	  	   	   	   2	  	   	   	   3	  	   	   	   4	  	   	   	   5	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Fisher	  grade:	  	   	   1	  	   	   	   2	  	   	   	   3	  	   	   	   4	  	   	  	   3+4	  	   	  
Hunt	  and	  Hess:	   0	  	   	   	   1	  	   	   	   2	  	   	   	   3	  	   	   	   4	  	   	   	  	  	  	  5	  	   	  	  
	  
Investigation	  
	  
CT-­‐Angiogram:	   Date	   ……./……/………	  	  
Aneurysm:	   	   R	   L	   	   	   	   	   R	   L	  Pericallosal	   	    	    	   Anterior	  Communicating	    	    	  Carotid	  Bifurcation	    	    	   Posterior	  Communicating	    	    	  Opthalmic	   	    	    	   Cavernous	   	   	    	    	  M1	   	   	    	    	   M2	   	   	   	    	    	  PICA	   	   	    	    	   Basilar	  Tip	   	   	    	    	  Basilar	  Trunk	  	    	    	   Other	   	   	   	    	    	   None	   	  	  
Formal	  Angiogram:	  Date	   ……./……./………	  
	  
Aneurysm:	   	   R	   L	   	   	   	   	   R	   L	  Pericallosal	   	    	    	   Anterior	  Communicating	    	    	  Carotid	  Bifurcation	    	    	   Posterior	  Communicating	    	    	  Opthalmic	   	    	    	   Cavernous	   	   	    	    	  M1	   	   	    	    	   M2	   	   	   	    	    	  PICA	   	   	    	    	   Basilar	  Tip	   	   	    	    	  Basilar	  Trunk	  	    	    	   Other	   	   	   	    	    	   None	   	  	  
Unruptured	  aneurysm?	   	   	   Yes	    	   No	    	  
	  
Prior	  sentinel	  bleeds?	   	   	   Yes	    	   No	    	  
	  
Presenting	  features	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Headache	   	   Glucose	   	   Lactate	   	  
Meningism	   	   Na	   	   FiO2	   	  
Altered	  
consciousness	  
	   K	   	   PO2	   	  
Vomiting	   	   Urea	   	   PCO2	   	  
Diplopia	   	   Creatinine	   	   pH	   	  
Confusion	   	   Lactate	   	   Pulse	   	  
Motor	  Deficit	   	   Albumin	   	   BP	   	  
Dysphasia	   	   Hb	   	   Resp	  Rate	   	  
Temperature	   	   Wcc	   	   Pupil	  reactivity-­‐L	   	  
	   	   Platelets	   	   Pupil	  size-­‐L	   	  
	   	   APTT	   	   Pupil	  reactivity-­‐R	   	  
	   	   PT	   	   Pupil	  size-­‐R	   	  
	   	   INR	   	   	   	  
Past	  Medical	  History	  	  DM	    	   HTN	    	   IHD	    	   MI	    	   PVD	    	   	  Other	  ………………………………………………………………………	  Previous	  Intracranial	  haemorrhage	    	   Stroke	    	  Family	  History	  of	  aneurysmal	  bleed	  ………………	  	  Smoker	  	  Y	  	   	  	  N	  	   	  	  
Examination	  Findings	  	   	   L	   	   	   R	  
	  
Cranial	  Nerve	  deficits:	  	   	   	   …….	   	   	   …….	  
	  
Upper	  Limb	  Tone	   	   	   	   	   	    	   	   	    	  	  Power	   	   Shoulder	  Abduction	   …….	   	   	   …….	   	  	   	   Shoulder	  Adduction	   …….	   	   	   …….	  	   	   Elbow	  Flexion	   	   …….	   	   	   …….	  	   	   Elbow	  Extension	   	   …….	   	   	   …….	   	   	  	   	   Wrist	  Flexion	   	   …….	   	   	   …….	  	   	   Wrist	  Extension	   	   …….	   	   	   …….	  	   	   Grip	   	   	   	   …….	   	   	   …….	  Sensation	   	   	   	   	   …….	   	   	   …….	  Reflexes	   Biceps	   	   	   …….	   	   	   …….	  	   	   Triceps	   	   	   …….	   	   	   …….	  	   	   Supinator	   	   	   …….	   	   	   …….	  Co-­‐ordination/Gait	  (impaired/normal)	   …….	   	   	   …….	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Lower	  Limb	   	   	   	   L	   	   	   R	  Tone	   	   	   	   	   	    	   	   	    	  Power	   	   Hip	  Flexion	  	   	   …….	   	   	   …….	   	  	   	   Hip	  Extension	   	   …….	   	   	   …….	  	   	   Knee	  Flexion	   	   …….	   	   	   …….	  	   	   Knee	  Extension	   	   …….	   	   	   …….	   	   	  	   	   Ankle	  Flexion	   	   …….	   	   	   …….	  	   	   Ankle	  Extension	   	   …….	   	   	   …….	  	   	   Toe	  Extension	   	   …….	   	   	   …….	  Sensation	   	   	   	   	   …….	   	   	   …….	  Reflexes	   Knee	   	   	   	   …….	   	   	   …….	  	   	   Ankle	  	   	   	   …….	   	   	   …….	  Co-­‐ordination/Gait	  (impaired/normal)	   …….	   	   	   …….	   	  
Treatment	  	  Coiling	  	  	    	   Date	   ……/……/………	  Clipping	    	   Date	   ……/……/………	  EVD	   	    	   Date	   ……/……/………	   	  	  Intra-­‐operative	  rupture?	   	   Yes	    	   No	    	  Temporary	  Clip	   	   	   Yes	    	   No	    	  	  Clip	  1:	  Time	  (min)…………..	   	   Clip	  2:	  Time	  (min)…………..	  	  Post	  op	  complication	  ……………………………………………………………….	  	  Post	  op	  neurological	  deterioration?	   Yes	    	   No	    	  	  Anaesthetic	  Problems	  ……………………………………………………...	  	  
Randomisation	  to	  Lumbar	  Drain	  Trial	  
	  Randomised	  to	  lumbar	  drain	  trial?	   Yes	    	   No	    	  	  If	  NO,	  why	  not?…………………………………………………………….	  	  If	  YES,	  randomised	  to:	   	   Drain	   	   Control	    	  Date	   ……/……/………	   	  	  If	  drain	  inserted:	   Opening	  pressure	  …………………………….	  	   	   	   Closing	  pressure	   …………………………….	  	   	   	   CSF	  colour	   	   …………………………….	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   Date	  Removed	   ……./……/………………..	  	  Delayed	  Neurological	  Deficit?	  Yes	    	   No	    	  Shunt	  Dependant?	   	   	   Yes	    	   No	    	  Date	  of	  discharge	  from	  high	  dependency………../………./…………	  	  Date	  neurosurgical	  input	  discontinued……../………./…………	  	  Date	  of	  discharge	  as	  neurosurgical	  input………./………./………….	  	  Place	  of	  discharge……………………………………………………	  	  
Notes	  	  …………………………………………………………………………………………..	  	  …………………………………………………………………………………………..	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Daily Progress  
Booklet	  for	  
Subarachnoid	  
Haemorrhage	  patient	  
included	  in	  the	  Lumbar	  
Drain	  Trial	  	  Name	  of	  Patient……………………	  Hospital	  Number…………………..	  	  Randomised	  to:	  Lumbar	  Drain	    	  Control	  Arm	  	    	  
	  
	  
When	  to	  use	  this	  document:	  to	  collect	  information	  on	  a	  daily	  
basis.	  Day	  0	  is	  day	  of	  haemorrhage.	  	  Day	  1	  is	  the	  following	  day	  
etc.	  	  This	  is	  regardless	  of	  date	  of	  admission.	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Daily	  progress	  sheet:	  Day	  1	  
 
Glasgow	  Coma	  Score	   	   	   	   	   Motor	  Examination
	   	  Best	  	  ……………	   M	   	  V	  	   	  	  E	  	   	  	   Normal	  X4	    	  Worst	  	  ………….	   M	   	  V	  	   	  	  E	  	   	  	   Weak	  arm	    	   L…….R…….	  	   	   	   	   	   	   	   	   Weak	  leg	    	   L…….R…….	  
Cranial	  Nerves	  Pupil	  size	  (mm)	  	  	   L…….R…….	  	   	   	   Other	  CNS	  Defect	   L…….R……	  Pupil	  reactive?	  (tick	  for	  yes)	   	  	  	  	   	  	  	  	  	   	   	  	   Describe	  defect	  ……………………	  
	  
Orientation	   	   	   	   	   Speech	  Full	  	    	   	   	   	   Fluent	  	   	    	  Partial	    	   	   	   	   Dysphasic	   	    	  None	    	   	   	   	   None	   	   	    	  Can’t	  assess	    	   	   	   	   Intubated/trach	    	  	  
Airway:	   Normal	   	  	  Adjuvant	  	   	  Tracheostomy	   	  	  ET	  tube	   	  	  
Ventilation-­‐number	  of	  hours	  of	  this	  support	  (max	  24	  hours):	  	  SIMV……….	  	  	  	  CPAP/BIPAP……….	  	  	  	  Wall	  CPAP……….	  	  	  	  None……….	  FiO2	  ………..	  	  	  	  PO2	  ………..	  	  	  	  PCO2	  ……….	  	  	  	  pH	  ……….	  
	  
MAP	  (periods	  >60	  mins	  tick	  boxes	  and	  write	  number	  of	  hours	  at	  this	  
MAP):	  0-­‐60	  	   ……	  	  	  60-­‐80	  	   ……	  	  	  80-­‐100	  	   ……	  	  	  100-­‐120	  	   ……	  	  	  120-­‐140	  	   ……	  	  >140	  	  
 …….	  Inotrope	  use?	   	  	  Y	  	   	   	   N	  	   	  	  Which	  one?………………….	  	  How	  much?………………..	  
CVP	  0-­‐4	  	   ……	  	  	  4-­‐8	  	   ……	  	  	  8-­‐12	  	   ……	  	  	  12-­‐16	  	   ……	  	  	  16-­‐20	  	   ……	  	  >20	  	   …….	  
Infection	  Screen:	  Max	  reproducible	  temp………CRP…………WCC……………Neut………Lymp……………	  
	  
CSF	   EVD:	  WCC……….	  RBC….……	  PM	  (%)………..	  Gram	  stain……….Org	  ……….....	  	   	   Volume/24	  hours……………...	  Colour……………………..	  
CSF	  Lumbar:	  WCC……….	  RBC………	  PM	  (%)………..	  Gram	  stain……….Org	  ……….......	  
 236	  
	   	   Volume/24	  hours………………	  Colour	  ……………………..	  
	  
Fluid	  intake:	  	   N.	  Saline	  ………….	   ml	   Gelofusin……….ml	   	  	  	  	  	  	  	  	  	  Voluven………….ml	   NG/Oral……….......	   ml	   Other:	   Type…………..	  Volume…………...ml	  	   	   	   Magnesium………/24	  h	  	  	  	   Statin?	  Y	  	   	   	  	  	  N	   	    	   	   Which	  one?………............	  
Fluid	  Output:	  	   Urine/24	  hours	  ……...	   L	   Other……………......	   L	  
	  
Other	  results:	  Na……….	  	  K……….	  Urea……….	  	  Creatinine……….	  	  Hb……….	  	  Platelets……….	  	  Serum	   osmolality………..	   Urine	   osmolality………...	   Urine	   Na:	   Spot……..	   24	  h………….	  Glucose………….	   Magnesium………..	  Albumin…………APTT………PT………..INR……….	  
Drain	   wound	  
concerns.....................................................................................................................	  
CT/CT-­‐A/P	  findings..………………………………………………………………………….	  
TCD	  ………………………………………………………………………………………………..	  ……………………………………………………………………………………………………..	  
 
 
